false 2021 Q2 0000891024--04-24 0000891024 2020-04-26 2020-10-24 xbrli:shares 0000891024 2020-11-25 iso4217:USD 0000891024 2020-10-24 0000891024 2020-04-25 iso4217:USD xbrli:shares 0000891024 2020-07-26 2020-10-24 0000891024 2019-07-28 2019-10-26 0000891024 2019-04-28 2019-10-26 0000891024 us-gaap:CommonStockMember 2019-04-27 0000891024 us-gaap:AdditionalPaidInCapitalMember 2019-04-27 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-27 0000891024 us-gaap:RetainedEarningsMember 2019-04-27 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2019-04-27 0000891024 us-gaap:NoncontrollingInterestMember 2019-04-27 0000891024 2019-04-27 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-28 2019-07-27 0000891024 2019-04-28 2019-07-27 0000891024 us-gaap:RetainedEarningsMember 2019-04-28 2019-07-27 0000891024 us-gaap:NoncontrollingInterestMember 2019-04-28 2019-07-27 0000891024 us-gaap:CommonStockMember 2019-04-28 2019-07-27 0000891024 us-gaap:AdditionalPaidInCapitalMember 2019-04-28 2019-07-27 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2019-04-28 2019-07-27 0000891024 us-gaap:RetainedEarningsMember pdco:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-04-27 0000891024 pdco:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-04-27 0000891024 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-28 2019-07-27 0000891024 us-gaap:RetainedEarningsMember us-gaap:AccountingStandardsUpdate201802Member 2019-04-28 2019-07-27 0000891024 us-gaap:CommonStockMember 2019-07-27 0000891024 us-gaap:AdditionalPaidInCapitalMember 2019-07-27 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-27 0000891024 us-gaap:RetainedEarningsMember 2019-07-27 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2019-07-27 0000891024 us-gaap:NoncontrollingInterestMember 2019-07-27 0000891024 2019-07-27 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-28 2019-10-26 0000891024 us-gaap:RetainedEarningsMember 2019-07-28 2019-10-26 0000891024 us-gaap:NoncontrollingInterestMember 2019-07-28 2019-10-26 0000891024 us-gaap:CommonStockMember 2019-07-28 2019-10-26 0000891024 us-gaap:AdditionalPaidInCapitalMember 2019-07-28 2019-10-26 0000891024 us-gaap:CommonStockMember 2019-10-26 0000891024 us-gaap:AdditionalPaidInCapitalMember 2019-10-26 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-26 0000891024 us-gaap:RetainedEarningsMember 2019-10-26 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2019-10-26 0000891024 us-gaap:NoncontrollingInterestMember 2019-10-26 0000891024 2019-10-26 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-27 2020-01-25 0000891024 2019-10-27 2020-01-25 0000891024 us-gaap:RetainedEarningsMember 2019-10-27 2020-01-25 0000891024 us-gaap:NoncontrollingInterestMember 2019-10-27 2020-01-25 0000891024 us-gaap:CommonStockMember 2019-10-27 2020-01-25 0000891024 us-gaap:AdditionalPaidInCapitalMember 2019-10-27 2020-01-25 0000891024 us-gaap:CommonStockMember 2020-01-25 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-01-25 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-25 0000891024 us-gaap:RetainedEarningsMember 2020-01-25 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2020-01-25 0000891024 us-gaap:NoncontrollingInterestMember 2020-01-25 0000891024 2020-01-25 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-26 2020-04-25 0000891024 2020-01-26 2020-04-25 0000891024 us-gaap:RetainedEarningsMember 2020-01-26 2020-04-25 0000891024 us-gaap:NoncontrollingInterestMember 2020-01-26 2020-04-25 0000891024 us-gaap:CommonStockMember 2020-01-26 2020-04-25 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-01-26 2020-04-25 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2020-01-26 2020-04-25 0000891024 us-gaap:CommonStockMember 2020-04-25 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-04-25 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-25 0000891024 us-gaap:RetainedEarningsMember 2020-04-25 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2020-04-25 0000891024 us-gaap:NoncontrollingInterestMember 2020-04-25 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-26 2020-07-25 0000891024 2020-04-26 2020-07-25 0000891024 us-gaap:RetainedEarningsMember 2020-04-26 2020-07-25 0000891024 us-gaap:NoncontrollingInterestMember 2020-04-26 2020-07-25 0000891024 us-gaap:CommonStockMember 2020-04-26 2020-07-25 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-04-26 2020-07-25 0000891024 us-gaap:CommonStockMember 2020-07-25 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-07-25 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-25 0000891024 us-gaap:RetainedEarningsMember 2020-07-25 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2020-07-25 0000891024 us-gaap:NoncontrollingInterestMember 2020-07-25 0000891024 2020-07-25 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-26 2020-10-24 0000891024 us-gaap:RetainedEarningsMember 2020-07-26 2020-10-24 0000891024 us-gaap:NoncontrollingInterestMember 2020-07-26 2020-10-24 0000891024 us-gaap:CommonStockMember 2020-07-26 2020-10-24 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-07-26 2020-10-24 0000891024 us-gaap:CommonStockMember 2020-10-24 0000891024 us-gaap:AdditionalPaidInCapitalMember 2020-10-24 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-24 0000891024 us-gaap:RetainedEarningsMember 2020-10-24 0000891024 pdco:NotesReceivableFromEmployeeStockOwnershipPlanMember 2020-10-24 0000891024 us-gaap:NoncontrollingInterestMember 2020-10-24 0000891024 us-gaap:StockCompensationPlanMember 2020-07-26 2020-10-24 0000891024 us-gaap:StockCompensationPlanMember 2020-04-26 2020-10-24 0000891024 pdco:ReceivablesPurchaseAgreementsMember 2020-10-24 0000891024 pdco:ReceivablesPurchaseAgreementsMember 2020-04-25 0000891024 pdco:ReceivablesPurchaseAgreementsMember 2020-04-26 2020-10-24 0000891024 pdco:ReceivablesPurchaseAgreementsMember 2019-04-28 2019-10-26 0000891024 pdco:ReceivablesPurchaseAgreementsMember 2019-04-27 0000891024 pdco:ReceivablesPurchaseAgreementsMember 2019-10-26 pdco:finance_agreement xbrli:pure 0000891024 pdco:BankOfTokyoMitsubishiUfjLimitedMember 2020-04-26 2020-10-24 0000891024 pdco:BankOfTokyoMitsubishiUfjLimitedMember 2020-10-24 0000891024 pdco:FifthThirdNationalBankMember 2020-04-26 2020-10-24 0000891024 pdco:FifthThirdNationalBankMember 2020-10-24 0000891024 pdco:CustomerFinanceContractsMember 2020-07-26 2020-10-24 0000891024 pdco:CustomerFinanceContractsMember 2019-07-28 2019-10-26 0000891024 pdco:CustomerFinanceContractsMember 2020-04-26 2020-10-24 0000891024 pdco:CustomerFinanceContractsMember 2019-04-28 2019-10-26 0000891024 pdco:UnsettledContractsMember 2020-10-24 0000891024 pdco:UnsettledContractsMember 2020-04-25 0000891024 pdco:CustomerFinanceContractsMember 2020-04-25 0000891024 pdco:CustomerFinanceContractsMember 2019-04-27 0000891024 pdco:CustomerFinanceContractsMember 2020-10-24 0000891024 pdco:CustomerFinanceContractsMember 2019-10-26 0000891024 us-gaap:InterestRateCapMember 2020-10-24 0000891024 pdco:NewInterestRateCapAgreementMember 2020-10-24 0000891024 pdco:InterestRateSwapAgreementMember pdco:FivePointOneSevenPercentageSeniorNotesMember 2014-01-31 0000891024 pdco:InterestRateSwapAgreementMember pdco:SeniorNotesSevenMember 2015-03-25 0000891024 pdco:InterestRateSwapAgreementMember 2015-03-01 2015-03-31 0000891024 us-gaap:InterestRateSwapMember 2020-04-25 0000891024 pdco:InterestRateSwapTwoMember 2020-10-24 0000891024 us-gaap:InterestRateSwapMember 2020-10-24 0000891024 pdco:InterestRateSwapAgreementMember 2020-04-26 2020-10-24 0000891024 pdco:InterestRateSwapAgreementMember 2019-07-28 2019-10-26 0000891024 us-gaap:InterestRateContractMember us-gaap:OtherNoncurrentAssetsMember 2020-10-24 0000891024 us-gaap:InterestRateContractMember us-gaap:OtherNoncurrentAssetsMember 2020-04-25 0000891024 us-gaap:InterestRateContractMember pdco:OtherAccruedLiabilitiesMember 2020-10-24 0000891024 us-gaap:InterestRateContractMember pdco:OtherAccruedLiabilitiesMember 2020-04-25 0000891024 us-gaap:InterestRateContractMember us-gaap:OtherNoncurrentLiabilitiesMember 2020-10-24 0000891024 us-gaap:InterestRateContractMember us-gaap:OtherNoncurrentLiabilitiesMember 2020-04-25 0000891024 us-gaap:InterestRateSwapMember 2020-07-26 2020-10-24 0000891024 us-gaap:InterestRateSwapMember 2019-07-28 2019-10-26 0000891024 us-gaap:InterestRateSwapMember 2020-04-26 2020-10-24 0000891024 us-gaap:InterestRateSwapMember 2019-04-28 2019-10-26 0000891024 us-gaap:NondesignatedMember us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-26 2020-10-24 0000891024 us-gaap:NondesignatedMember us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-28 2019-10-26 0000891024 us-gaap:NondesignatedMember us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-04-26 2020-10-24 0000891024 us-gaap:NondesignatedMember us-gaap:InterestRateSwapMember 2019-04-28 2019-10-26 0000891024 us-gaap:FairValueInputsLevel1Member 2020-10-24 0000891024 us-gaap:FairValueInputsLevel2Member 2020-10-24 0000891024 us-gaap:FairValueInputsLevel3Member 2020-10-24 0000891024 us-gaap:FairValueInputsLevel1Member 2020-04-25 0000891024 us-gaap:FairValueInputsLevel2Member 2020-04-25 0000891024 us-gaap:FairValueInputsLevel3Member 2020-04-25 0000891024 pdco:TechnologyPartnerInnovationsLLCMember 2018-04-29 2019-04-27 0000891024 pdco:TechnologyPartnerInnovationsLLCMember 2020-07-26 2020-10-24 0000891024 pdco:TechnologyPartnerInnovationsLLCMember 2019-07-28 2019-10-26 0000891024 pdco:TechnologyPartnerInnovationsLLCMember 2020-04-26 2020-10-24 0000891024 pdco:TechnologyPartnerInnovationsLLCMember 2019-04-28 2019-10-26 0000891024 pdco:TechnologyPartnerInnovationsLLCMember 2020-10-24 pdco:Segment 0000891024 country:US 2020-07-26 2020-10-24 0000891024 country:US 2019-07-28 2019-10-26 0000891024 country:US 2020-04-26 2020-10-24 0000891024 country:US 2019-04-28 2019-10-26 0000891024 country:GB 2020-07-26 2020-10-24 0000891024 country:GB 2019-07-28 2019-10-26 0000891024 country:GB 2020-04-26 2020-10-24 0000891024 country:GB 2019-04-28 2019-10-26 0000891024 country:CA 2020-07-26 2020-10-24 0000891024 country:CA 2019-07-28 2019-10-26 0000891024 country:CA 2020-04-26 2020-10-24 0000891024 country:CA 2019-04-28 2019-10-26 0000891024 country:US pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 country:US pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 country:US pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 country:US pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 country:CA pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 country:CA pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 country:CA pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 country:CA pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 pdco:AnimalHealthMember country:US 2020-07-26 2020-10-24 0000891024 pdco:AnimalHealthMember country:US 2019-07-28 2019-10-26 0000891024 pdco:AnimalHealthMember country:US 2020-04-26 2020-10-24 0000891024 pdco:AnimalHealthMember country:US 2019-04-28 2019-10-26 0000891024 country:GB pdco:AnimalHealthMember 2020-07-26 2020-10-24 0000891024 country:GB pdco:AnimalHealthMember 2019-07-28 2019-10-26 0000891024 country:GB pdco:AnimalHealthMember 2020-04-26 2020-10-24 0000891024 country:GB pdco:AnimalHealthMember 2019-04-28 2019-10-26 0000891024 country:CA pdco:AnimalHealthMember 2020-07-26 2020-10-24 0000891024 country:CA pdco:AnimalHealthMember 2019-07-28 2019-10-26 0000891024 country:CA pdco:AnimalHealthMember 2020-04-26 2020-10-24 0000891024 country:CA pdco:AnimalHealthMember 2019-04-28 2019-10-26 0000891024 pdco:AnimalHealthMember 2020-07-26 2020-10-24 0000891024 pdco:AnimalHealthMember 2019-07-28 2019-10-26 0000891024 pdco:AnimalHealthMember 2020-04-26 2020-10-24 0000891024 pdco:AnimalHealthMember 2019-04-28 2019-10-26 0000891024 us-gaap:CorporateMember country:US 2020-07-26 2020-10-24 0000891024 us-gaap:CorporateMember country:US 2019-07-28 2019-10-26 0000891024 us-gaap:CorporateMember country:US 2020-04-26 2020-10-24 0000891024 us-gaap:CorporateMember country:US 2019-04-28 2019-10-26 0000891024 us-gaap:CorporateMember 2020-07-26 2020-10-24 0000891024 us-gaap:CorporateMember 2019-07-28 2019-10-26 0000891024 us-gaap:CorporateMember 2020-04-26 2020-10-24 0000891024 us-gaap:CorporateMember 2019-04-28 2019-10-26 0000891024 pdco:ConsumablesMember 2020-07-26 2020-10-24 0000891024 pdco:ConsumablesMember 2019-07-28 2019-10-26 0000891024 pdco:ConsumablesMember 2020-04-26 2020-10-24 0000891024 pdco:ConsumablesMember 2019-04-28 2019-10-26 0000891024 pdco:EquipmentAndSoftwareMember 2020-07-26 2020-10-24 0000891024 pdco:EquipmentAndSoftwareMember 2019-07-28 2019-10-26 0000891024 pdco:EquipmentAndSoftwareMember 2020-04-26 2020-10-24 0000891024 pdco:EquipmentAndSoftwareMember 2019-04-28 2019-10-26 0000891024 pdco:OtherProductMember 2020-07-26 2020-10-24 0000891024 pdco:OtherProductMember 2019-07-28 2019-10-26 0000891024 pdco:OtherProductMember 2020-04-26 2020-10-24 0000891024 pdco:OtherProductMember 2019-04-28 2019-10-26 0000891024 pdco:ConsumablesMember pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 pdco:ConsumablesMember pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 pdco:ConsumablesMember pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 pdco:ConsumablesMember pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 pdco:EquipmentAndSoftwareMember pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 pdco:EquipmentAndSoftwareMember pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 pdco:EquipmentAndSoftwareMember pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 pdco:EquipmentAndSoftwareMember pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 pdco:OtherProductMember pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 pdco:OtherProductMember pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 pdco:OtherProductMember pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 pdco:OtherProductMember pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 pdco:ConsumablesMember pdco:AnimalHealthMember 2020-07-26 2020-10-24 0000891024 pdco:ConsumablesMember pdco:AnimalHealthMember 2019-07-28 2019-10-26 0000891024 pdco:ConsumablesMember pdco:AnimalHealthMember 2020-04-26 2020-10-24 0000891024 pdco:ConsumablesMember pdco:AnimalHealthMember 2019-04-28 2019-10-26 0000891024 pdco:EquipmentAndSoftwareMember pdco:AnimalHealthMember 2020-07-26 2020-10-24 0000891024 pdco:EquipmentAndSoftwareMember pdco:AnimalHealthMember 2019-07-28 2019-10-26 0000891024 pdco:EquipmentAndSoftwareMember pdco:AnimalHealthMember 2020-04-26 2020-10-24 0000891024 pdco:EquipmentAndSoftwareMember pdco:AnimalHealthMember 2019-04-28 2019-10-26 0000891024 pdco:OtherProductMember pdco:AnimalHealthMember 2020-07-26 2020-10-24 0000891024 pdco:OtherProductMember pdco:AnimalHealthMember 2019-07-28 2019-10-26 0000891024 pdco:OtherProductMember pdco:AnimalHealthMember 2020-04-26 2020-10-24 0000891024 pdco:OtherProductMember pdco:AnimalHealthMember 2019-04-28 2019-10-26 0000891024 pdco:OtherProductMember us-gaap:CorporateMember 2020-07-26 2020-10-24 0000891024 pdco:OtherProductMember us-gaap:CorporateMember 2019-07-28 2019-10-26 0000891024 pdco:OtherProductMember us-gaap:CorporateMember 2020-04-26 2020-10-24 0000891024 pdco:OtherProductMember us-gaap:CorporateMember 2019-04-28 2019-10-26 0000891024 us-gaap:OperatingSegmentsMember pdco:DentalSupplyMember 2020-07-26 2020-10-24 0000891024 us-gaap:OperatingSegmentsMember pdco:DentalSupplyMember 2019-07-28 2019-10-26 0000891024 us-gaap:OperatingSegmentsMember pdco:DentalSupplyMember 2020-04-26 2020-10-24 0000891024 us-gaap:OperatingSegmentsMember pdco:DentalSupplyMember 2019-04-28 2019-10-26 0000891024 pdco:AnimalHealthMember us-gaap:OperatingSegmentsMember 2020-07-26 2020-10-24 0000891024 pdco:AnimalHealthMember us-gaap:OperatingSegmentsMember 2019-07-28 2019-10-26 0000891024 pdco:AnimalHealthMember us-gaap:OperatingSegmentsMember 2020-04-26 2020-10-24 0000891024 pdco:AnimalHealthMember us-gaap:OperatingSegmentsMember 2019-04-28 2019-10-26 0000891024 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2020-07-26 2020-10-24 0000891024 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2019-07-28 2019-10-26 0000891024 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2020-04-26 2020-10-24 0000891024 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2019-04-28 2019-10-26 0000891024 us-gaap:OperatingSegmentsMember pdco:DentalSupplyMember 2020-10-24 0000891024 us-gaap:OperatingSegmentsMember pdco:DentalSupplyMember 2020-04-25 0000891024 pdco:AnimalHealthMember us-gaap:OperatingSegmentsMember 2020-10-24 0000891024 pdco:AnimalHealthMember us-gaap:OperatingSegmentsMember 2020-04-25 0000891024 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2020-10-24 0000891024 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2020-04-25 0000891024 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-04-25 0000891024 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-25 0000891024 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-04-26 2020-10-24 0000891024 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-26 2020-10-24 0000891024 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-26 2020-10-24 0000891024 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-10-24 0000891024 us-gaap:AccumulatedTranslationAdjustmentMember 2020-10-24 0000891024 pdco:KirstenJohnsenV.ScottPAndersonEtAlMember 2018-10-01 2018-10-01 0000891024 pdco:KirstenJohnsenV.ScottPAndersonEtAlMember 2018-08-28 2018-08-28
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 10-Q
____________________________________________________________

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED October 24, 2020.

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 0-20572
__________________________________________________________
PATTERSON COMPANIES, INC.
(Exact Name of Registrant as Specified in Its Charter)
____________________________________________________________

Minnesota | 41-0886515
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number)
1031 Mendota Heights Road |
St. Paul | Minnesota | 55120
(Address of Principal Executive Offices) | (Zip Code)

(651) 686-1600
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of exchange on which registered
Common Stock, par value $.01 | PDCO | NASDAQ Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐ |  | Non-accelerated filer |  | ☐
Smaller reporting company |  | ☐ |  | Emerging growth company |  | ☐ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of November 25, 2020, there were 96,504,000 shares of Common Stock of the registrant issued and outstanding.

Table of Contents
PATTERSON COMPANIES, INC.
INDEX

| Page
PART I - FINANCIAL INFORMATION |
Item 1- Financial Statements | 3
Condensed Consolidated Balance Sheets | 3
Condensed Consolidated Statements of Operations and Other Comprehensive Income | 4
Condensed Consolidated Statements of Changes in Stockholders' Equity | 5
Condensed Consolidated Statements of Cash Flows | 7
Notes to Condensed Consolidated Financial Statements | 8
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations | 20
Item 3 - Quantitative and Qualitative Disclosures about Market Risk | 26
Item 4 - Controls and Procedures | 26
PART II - OTHER INFORMATION |
Item 1 - Legal Proceedings | 28
Item 1A - Risk Factors | 28
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds | 29
Item 6 - Exhibits | 31
Signatures | 32

2

Table of Contents
PART I—FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
(Unaudited)

| October 24, 2020 |  | April 25, 2020
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 139,481 |  |  | $ | 77,944 |
Receivables, net of allowance for doubtful accounts of $6,421 and $5,123 | 491,687 |  |  | 416,523 |
Inventory | 761,941 |  |  | 812,194 |
Prepaid expenses and other current assets | 263,149 |  |  | 236,104 |
Total current assets | 1,656,258 |  |  | 1,542,765 |
Property and equipment, net | 298,460 |  |  | 303,725 |
Operating lease right-of-use assets, net | 81,171 |  |  | 79,021 |
Long-term receivables, net | 193,810 |  |  | 214,915 |
Goodwill, net | 139,411 |  |  | 138,724 |
Identifiable intangibles, net | 296,271 |  |  | 313,505 |
Other non-current assets | 123,643 |  |  | 122,695 |
Total assets | $ | 2,789,024 |  |  | $ | 2,715,350 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 690,755 |  |  | $ | 862,093 |
Accrued payroll expense | 78,224 |  |  | 68,385 |
Other accrued liabilities | 161,093 |  |  | 113,714 |
Operating lease liabilities | 31,814 |  |  | 30,706 |
Borrowings on revolving credit | 111,000 |  |  | — |
Total current liabilities | 1,072,886 |  |  | 1,074,898 |
Long-term debt | 588,329 |  |  | 587,766 |
Non-current operating lease liabilities | 53,796 |  |  | 49,854 |
Other non-current liabilities | 181,286 |  |  | 166,388 |
Total liabilities | 1,896,297 |  |  | 1,878,906 |
Stockholders’ equity: |  |  |
Common stock, $0.01 par value: 600,000 shares authorized; 96,495 and 95,947 shares issued and outstanding | 965 |  |  | 959 |
Additional paid-in capital | 157,793 |  |  | 146,606 |
Accumulated other comprehensive loss | (80,602) |  |  | (97,039) |
Retained earnings | 828,744 |  |  | 799,652 |
Unearned ESOP shares | (16,061) |  |  | (16,061) |
Total Patterson Companies, Inc. stockholders' equity | 890,839 |  |  | 834,117 |
Noncontrolling interests | 1,888 |  |  | 2,327 |
Total stockholders’ equity | 892,727 |  |  | 836,444 |
Total liabilities and stockholders’ equity | $ | 2,789,024 |  |  | $ | 2,715,350 |

See accompanying notes
3

Table of Contents
PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND OTHER COMPREHENSIVE INCOME
(In thousands, except per share amounts)
(Unaudited)

| Three Months Ended |  | Six Months Ended
| October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Net sales | $ | 1,553,168 |  |  | $ | 1,418,744 |  |  | $ | 2,799,005 |  |  | $ | 2,747,395 |
Cost of sales | 1,232,800 |  |  | 1,117,250 |  |  | 2,224,821 |  |  | 2,155,847 |
Gross profit | 320,368 |  |  | 301,494 |  |  | 574,184 |  |  | 591,548 |
Operating expenses | 246,662 |  |  | 319,640 |  |  | 462,606 |  |  | 593,020 |
Operating income (loss) | 73,706 |  |  | (18,146) |  |  | 111,578 |  |  | (1,472) |
Other income (expense): |  |  |  |  |  |  |
Other income, net | 3,223 |  |  | 269 |  |  | 5,257 |  |  | 32,186 |
Interest expense | (6,381) |  |  | (9,046) |  |  | (13,072) |  |  | (17,736) |
Income (loss) before taxes | 70,548 |  |  | (26,923) |  |  | 103,763 |  |  | 12,978 |
Income tax expense | 16,722 |  |  | 6,426 |  |  | 25,735 |  |  | 16,520 |
Net income (loss) | 53,826 |  |  | (33,349) |  |  | 78,028 |  |  | (3,542) |
Net loss attributable to noncontrolling interests | (234) |  |  | (220) |  |  | (439) |  |  | (455) |
Net income (loss) attributable to Patterson Companies, Inc. | $ | 54,060 |  |  | $ | (33,129) |  |  | $ | 78,467 |  |  | $ | (3,087) |
Earnings (loss) per share attributable to Patterson Companies, Inc.: |  |  |  |  |  |  |
Basic | $ | 0.57 |  |  | $ | (0.35) |  |  | $ | 0.82 |  |  | $ | (0.03) |
Diluted | $ | 0.56 |  |  | $ | (0.35) |  |  | $ | 0.82 |  |  | $ | (0.03) |
Weighted average shares: |  |  |  |  |  |  |
Basic | 95,518 |  |  | 94,093 |  |  | 95,341 |  |  | 93,944 |
Diluted | 96,415 |  |  | 94,093 |  |  | 96,105 |  |  | 93,944 |
Dividends declared per common share | $ | 0.26 |  |  | $ | 0.26 |  |  | $ | 0.52 |  |  | $ | 0.52 |
Comprehensive income (loss): |  |  |  |  |  |  |
Net income (loss) | $ | 53,826 |  |  | $ | (33,349) |  |  | $ | 78,028 |  |  | $ | (3,542) |
Foreign currency translation gain | 3,327 |  |  | 6,614 |  |  | 15,916 |  |  | 2,815 |
Cash flow hedges, net of tax | 261 |  |  | 554 |  |  | 521 |  |  | 1,108 |
Comprehensive income (loss) | $ | 57,414 |  |  | $ | (26,181) |  |  | $ | 94,465 |  |  | $ | 381 |

See accompanying notes
4

Table of Contents
PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)

| Common Stock |  | Additional Paid-in Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Unearned ESOP Shares |  | Non-controlling Interests |  | Total
| Shares |  | Amount |  |  |  |  |  |
Balance at April 27, 2019 | 95,272 |  |  | $ | 953 |  |  | $ | 131,460 |  |  | $ | (88,269) |  |  | $ | 1,483,496 |  |  | $ | (50,381) |  |  | $ | 3,248 |  |  | $ | 1,480,507 |
Foreign currency translation | — |  |  | — |  |  | — |  |  | (3,799) |  |  | — |  |  | — |  |  | — |  |  | (3,799) |
Cash flow hedges | — |  |  | — |  |  | — |  |  | 554 |  |  | — |  |  | — |  |  | — |  |  | 554 |
Net income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 30,042 |  |  | — |  |  | (235) |  |  | 29,807 |
Dividends declared | — |  |  | — |  |  | — |  |  | — |  |  | (24,856) |  |  | — |  |  | — |  |  | (24,856) |
Common stock issued and related tax benefits | 198 |  |  | 2 |  |  | (5,371) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (5,369) |
Stock based compensation | — |  |  | — |  |  | 6,634 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 6,634 |
ESOP activity | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 18,452 |  |  | — |  |  | 18,452 |
Adoption of ASU 2016-02 | — |  |  | — |  |  | — |  |  | — |  |  | 1,447 |  |  | — |  |  | — |  |  | 1,447 |
Adoption of ASU 2018-02 | — |  |  | — |  |  | — |  |  | (2,707) |  |  | 2,707 |  |  | — |  |  | — |  |  | — |
Balance at July 27, 2019 | 95,470 |  |  | 955 |  |  | 132,723 |  |  | (94,221) |  |  | 1,492,836 |  |  | (31,929) |  |  | 3,013 |  |  | 1,503,377 |
Foreign currency translation | — |  |  | — |  |  | — |  |  | 6,614 |  |  | — |  |  | — |  |  | — |  |  | 6,614 |
Cash flow hedges | — |  |  | — |  |  | — |  |  | 554 |  |  | — |  |  | — |  |  | — |  |  | 554 |
Net income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | (33,129) |  |  | — |  |  | (220) |  |  | (33,349) |
Dividends declared | — |  |  | — |  |  | — |  |  | — |  |  | (24,874) |  |  | — |  |  | — |  |  | (24,874) |
Common stock issued and related tax benefits | 245 |  |  | 2 |  |  | 731 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 733 |
Stock based compensation | — |  |  | — |  |  | 5,569 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 5,569 |
Balance at October 26, 2019 | 95,715 |  |  | 957 |  |  | 139,023 |  |  | (87,053) |  |  | 1,434,833 |  |  | (31,929) |  |  | 2,793 |  |  | 1,458,624 |
Foreign currency translation | — |  |  | — |  |  | — |  |  | 2,619 |  |  | — |  |  | — |  |  | — |  |  | 2,619 |
Cash flow hedges | — |  |  | — |  |  | — |  |  | 6,627 |  |  | — |  |  | — |  |  | — |  |  | 6,627 |
Net income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 23,227 |  |  | — |  |  | (255) |  |  | 22,972 |
Dividends declared | — |  |  | — |  |  | — |  |  | — |  |  | (24,897) |  |  | — |  |  | — |  |  | (24,897) |
Common stock issued and related tax benefits | 77 |  |  | 1 |  |  | 463 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 464 |
Stock based compensation | — |  |  | — |  |  | 5,559 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 5,559 |
Balance at January 25, 2020 | 95,792 |  |  | 958 |  |  | 145,045 |  |  | (77,807) |  |  | 1,433,163 |  |  | (31,929) |  |  | 2,538 |  |  | 1,471,968 |
Foreign currency translation | — |  |  | — |  |  | — |  |  | (19,496) |  |  | — |  |  | — |  |  | — |  |  | (19,496) |
Cash flow hedges | — |  |  | — |  |  | — |  |  | 264 |  |  | — |  |  | — |  |  | — |  |  | 264 |
Net income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | (608,586) |  |  | — |  |  | (211) |  |  | (608,797) |
Dividends declared | — |  |  | — |  |  | — |  |  | — |  |  | (24,925) |  |  | — |  |  | — |  |  | (24,925) |
Common stock issued and related tax benefits | 155 |  |  | 1 |  |  | (3,613) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3,612) |
Stock based compensation | — |  |  | — |  |  | 5,174 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 5,174 |
ESOP activity | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15,868 |  |  | — |  |  | 15,868 |
Balance at April 25, 2020 | 95,947 |  |  | $ | 959 |  |  | $ | 146,606 |  |  | $ | (97,039) |  |  | $ | 799,652 |  |  | $ | (16,061) |  |  | $ | 2,327 |  |  | $ | 836,444 |

See accompanying notes
5

Table of Contents
PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)

| Common Stock |  | Additional Paid-in Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Unearned ESOP Shares |  | Non-controlling Interests |  | Total
| Shares |  | Amount |  |  |  |  |  |
Balance at April 25, 2020 | 95,947 |  |  | $ | 959 |  |  | $ | 146,606 |  |  | $ | (97,039) |  |  | $ | 799,652 |  |  | $ | (16,061) |  |  | $ | 2,327 |  |  | $ | 836,444 |
Foreign currency translation | — |  |  | — |  |  | — |  |  | 12,589 |  |  | — |  |  | — |  |  | — |  |  | 12,589 |
Cash flow hedges | — |  |  | — |  |  | — |  |  | 260 |  |  | — |  |  | — |  |  | — |  |  | 260 |
Net income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 24,407 |  |  | — |  |  | (205) |  |  | 24,202 |
Dividends declared | — |  |  | — |  |  | — |  |  | — |  |  | (24,472) |  |  | — |  |  | — |  |  | (24,472) |
Common stock issued and related tax benefits | 309 |  |  | 4 |  |  | (899) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (895) |
Stock based compensation | — |  |  | — |  |  | 6,610 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 6,610 |
Balance at July 25, 2020 | 96,256 |  |  | 963 |  |  | 152,317 |  |  | (84,190) |  |  | 799,587 |  |  | (16,061) |  |  | 2,122 |  |  | 854,738 |
Foreign currency translation | — |  |  | — |  |  | — |  |  | 3,327 |  |  | — |  |  | — |  |  | — |  |  | 3,327 |
Cash flow hedges | — |  |  | — |  |  | — |  |  | 261 |  |  | — |  |  | — |  |  | — |  |  | 261 |
Net income (loss) | — |  |  | — |  |  | — |  |  | — |  |  | 54,060 |  |  | — |  |  | (234) |  |  | 53,826 |
Dividends declared | — |  |  | — |  |  | — |  |  | — |  |  | (24,903) |  |  | — |  |  | — |  |  | (24,903) |
Common stock issued and related tax benefits | 240 |  |  | 2 |  |  | 1,209 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,211 |
Stock based compensation | — |  |  | — |  |  | 4,267 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 4,267 |
Balance at October 24, 2020 | 96,496 |  |  | $ | 965 |  |  | $ | 157,793 |  |  | $ | (80,602) |  |  | $ | 828,744 |  |  | $ | (16,061) |  |  | $ | 1,888 |  |  | $ | 892,727 |

See accompanying notes
6

Table of Contents
PATTERSON COMPANIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

| Six Months Ended
| October 24, 2020 |  | October 26, 2019
Operating activities: |  |  |
Net income (loss) | $ | 78,028 |  |  | $ | (3,542) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
Depreciation | 20,272 |  |  | 22,695 |
Amortization | 18,609 |  |  | 18,580 |
Investment gain | — |  |  | (34,334) |
Non-cash employee compensation | 16,660 |  |  | 19,302 |
Non-cash losses (gains) and other, net | 5,976 |  |  | — |
Change in assets and liabilities: |  |  |
Receivables | (505,535) |  |  | (209,100) |
Inventory | 58,238 |  |  | (27,238) |
Accounts payable | (179,276) |  |  | 118,301 |
Accrued liabilities | 24,555 |  |  | 102,301 |
Long term receivables | 687 |  |  | (4,292) |
Other changes from operating activities, net | 38,782 |  |  | (17,326) |
Net cash used in operating activities | (423,004) |  |  | (14,653) |
Investing activities: |  |  |
Additions to property and equipment | (14,370) |  |  | (22,851) |
Collection of deferred purchase price receivables | 408,907 |  |  | 212,307 |
Other investing activities | 396 |  |  | — |
Net cash provided by investing activities | 394,933 |  |  | 189,456 |
Financing activities: |  |  |
Dividends paid | (25,009) |  |  | (50,504) |
Payments on long-term debt | — |  |  | (87,090) |
Draw on revolving credit | 111,000 |  |  | — |
Other financing activities | 631 |  |  | (4,067) |
Net cash provided by (used in) financing activities | 86,622 |  |  | (141,661) |
Effect of exchange rate changes on cash | 2,986 |  |  | 787 |
Net change in cash and cash equivalents | 61,537 |  |  | 33,929 |
Cash and cash equivalents at beginning of period | 77,944 |  |  | 95,646 |
Cash and cash equivalents at end of period | $ | 139,481 |  |  | $ | 129,575 |
Supplemental disclosure of non-cash investing activity: |  |  |
Retained interest in securitization transactions | $ | 437,330 |  |  | $ | 211,056 |

See accompanying notes
7

Table of Contents
PATTERSON COMPANIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars, except per share amounts, and shares in thousands)
(Unaudited)
Note 1. General
Basis of Presentation
In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of Patterson Companies, Inc. (referred to herein as "Patterson" or in the first person notations "we," "our," and "us") as of October 24, 2020, and our results of operations and cash flows for the periods ended October 24, 2020 and October 26, 2019. Such adjustments are of a normal recurring nature. The results of operations for the three and six months ended October 24, 2020 are not necessarily indicative of the results to be expected for any other interim period or for the year ending April 24, 2021. These financial statements should be read in conjunction with the financial statements included in our 2020 Annual Report on Form 10-K filed on June 24, 2020.
The unaudited condensed consolidated financial statements include the assets and liabilities of PDC Funding Company, LLC ("PDC Funding"), PDC Funding Company II, LLC ("PDC Funding II"), PDC Funding Company III, LLC ("PDC Funding III") and PDC Funding Company IV, LLC ("PDC Funding IV"), which are our wholly owned subsidiaries and separate legal entities formed under Minnesota law. PDC Funding and PDC Funding II are fully consolidated special purpose entities established to sell customer installment sale contracts to outside financial institutions in the normal course of their business. PDC Funding III and PDC Funding IV are fully consolidated special purpose entity established to sell certain receivables to unaffiliated financial institutions. The assets of PDC Funding, PDC Funding II, PDC Funding III and PDC Funding IV would be available first and foremost to satisfy the claims of its creditors. There are no known creditors of PDC Funding, PDC Funding II, PDC Funding III or PDC Funding IV. The unaudited condensed consolidated financial statements also include the assets and liabilities of Technology Partner Innovations, LLC, which is further described in Note 7.
Fiscal Year End
We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The second quarter of fiscal 2021 and 2020 represents the 13 weeks ended October 24, 2020 and the 13 weeks ended October 26, 2019, respectively. The six months ended October 24, 2020 and October 26, 2019 each included 26 weeks. Fiscal 2021 will include 52 weeks and fiscal 2020 included 52 weeks.
Other Income, Net
Other income, net consisted of the following:

| Three Months Ended |  | Six Months Ended
| October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Gain on investment | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 34,334 |
Gain (loss) on interest rate swap agreements | 415 |  |  | (1,778) |  |  | (780) |  |  | (5,563) |
Other | 2,808 |  |  | 2,047 |  |  | 6,037 |  |  | 3,415 |
Other income, net | $ | 3,223 |  |  | $ | 269 |  |  | $ | 5,257 |  |  | $ | 32,186 |

Comprehensive Income
Comprehensive income is computed as net income including certain other items that are recorded directly to stockholders’ equity. Significant items included in comprehensive income are foreign currency translation adjustments and the effective portion of cash flow hedges, net of tax. Foreign currency translation adjustments do not include a provision for income tax because earnings from foreign operations are considered to be indefinitely reinvested outside the U.S. The income tax expense related to cash flow hedges was $81 and $171 for the three months ended October 24, 2020 and October 26, 2019, respectively. The income tax expense related to cash flow hedges was $161 and $342 for the six months ended October 24, 2020 and October 26, 2019, respectively.
8

Table of Contents
Earnings (Loss) Per Share ("EPS")
The following table sets forth the computation of the weighted average shares outstanding used to calculate basic and diluted EPS:

| Three Months Ended |  | Six Months Ended
| October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Denominator for basic EPS – weighted average shares | 95,518 |  |  | 94,093 |  |  | 95,341 |  |  | 93,944 |
Effect of dilutive securities – stock options, restricted stock and stock purchase plans | 897 |  |  | — |  |  | 764 |  |  | — |
Denominator for diluted EPS – weighted average shares | 96,415 |  |  | 94,093 |  |  | 96,105 |  |  | 93,944 |

Potentially dilutive securities representing 1,178 shares and 2,524 shares for the three and six months ended October 24, 2020, respectively, and 3,595 shares and 2,880 shares for the three and six months ended October 26, 2019, respectively, were excluded from the calculation of diluted EPS because their effects were anti-dilutive using the treasury stock method.
For the three and six months ended October 26, 2019, 707 and 769 incremental shares related to dilutive securities, respectively, were not included in the diluted EPS calculation because we reported a loss for these periods. Shares related to dilutive securities have an anti-dilutive impact on EPS when a net loss is reported and therefore are not included in the calculation.
Revenue Recognition
Revenues are generated from the sale of consumable products, equipment and support, software and support, technical service parts and labor, and other sources. Revenues are recognized when or as performance obligations are satisfied. Performance obligations are satisfied when the customer obtains control of the goods or services.
Consumable, equipment, software and parts sales are recorded upon delivery, except in those circumstances where terms of the sale are FOB shipping point, in which case sales are recorded upon shipment. Technical service labor is recognized as it is provided. Revenue derived from equipment and software support is recognized ratably over the period in which the support is provided.
In addition to revenues generated from the distribution of consumable products under arrangements (buy/sell agreements) where the full market value of the product is recorded as revenue, we earn commissions for services provided under agency agreements. The agency agreement contrasts to a buy/sell agreement in that we do not have control over the transaction, as we do not have the primary responsibility of fulfilling the promise of the good or service and we do not bill or collect from the customer in an agency relationship. Commissions under agency agreements are recorded when the services are provided.
Estimates for returns, damaged goods, rebates, loyalty programs and other revenue allowances are made at the time the revenue is recognized based on the historical experience for such items. The receivables that result from the recognition of revenue are reported net of related allowances. We maintain a valuation allowance based upon the expected collectability of receivables held. Estimates are used to determine the valuation allowance and are based on several factors, including historical collection data, current and forecasted economic trends and credit worthiness of customers. Receivables are written off when we determine the amounts to be uncollectible, typically upon customer bankruptcy or non-response to continuous collection efforts. The portions of receivable amounts that are not expected to be collected during the next twelve months are classified as long-term.
Net sales do not include sales tax as we are considered a pass-through conduit for collecting and remitting sales tax.
Contract Balances
Contract balances represent amounts presented in our condensed consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities.
9

Table of Contents
Contract asset balances as of October 24, 2020 and April 25, 2020 were $0 and $1,586, respectively. Our contract liabilities primarily relate to advance payments from customers, upfront payments for software and support provided over time, and options that provide a material right to customers, such as our customer loyalty programs. At October 24, 2020 and April 25, 2020, contract liabilities of $22,261 and $21,205 were reported in other accrued liabilities, respectively. During the six months ended October 24, 2020, we recognized $9,284 of the amount previously deferred at April 25, 2020.
Recently Issued Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326),” which requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. We adopted the new guidance in the first quarter of fiscal 2021, and it did not have a material impact on our condensed consolidated financial statements.
Reclassifications
Certain prior period amounts in the condensed consolidated statements of cash flows have been reclassified to conform to the current year presentation.
Note 2. Receivables Securitization Program
We are party to certain receivables purchase agreements (the “Receivables Purchase Agreements”) with MUFG Bank, Ltd. ("MUFG") (f.k.a. The Bank of Tokyo-Mitsubishi UFJ, Ltd.), under which MUFG acts as an agent to facilitate the sale of certain Patterson receivables (the “Receivables”) to certain unaffiliated financial institutions (the “Purchasers”). The sale of these receivables is accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing. We utilize PDC Funding III and PDC Funding IV to facilitate the sale to fulfill requirements within the agreement. We use a daily unit of account for these Receivables.
The proceeds from the sale of these Receivables comprise a combination of cash and a deferred purchase price (“DPP”) receivable. The DPP receivable is ultimately realized by Patterson following the collection of the underlying Receivables sold to the Purchasers. The amount available under the Receivables Purchase Agreements fluctuates over time based on the total amount of eligible Receivables generated during the normal course of business, with maximum availability of $200,000 as of October 24, 2020, of which $200,000 was utilized.
We have no retained interests in the transferred Receivables, other than our right to the DPP receivable and collection and administrative service fees. We consider the fees received adequate compensation for services rendered, and accordingly have recorded no servicing asset or liability. As of October 24, 2020 and April 25, 2020, the fair value of outstanding trade receivables transferred to the Purchasers under the facility and derecognized from the condensed consolidated balance sheets were $368,937 and $305,020, respectively. Sales of trade receivables under this facility were $1,507,189 and $981,973, and cash collections from customers on receivables sold were $1,442,620 and $955,705 during the six months ended October 24, 2020 and October 26, 2019, respectively.
The DPP receivable is recorded at fair value within the condensed consolidated balance sheets within prepaid expenses and other current assets. The difference between the carrying amount of the Receivables and the sum of the cash and fair value of the DPP receivable received at time of transfer is recognized as a gain or loss on sale of the related Receivables inclusive of bank fees and allowance for credit losses. We recorded a loss on sale of Receivables within operating expenses in the condensed consolidated statements of operations and other comprehensive income of $615 and $2,067 during the three months ended October 24, 2020 and October 26, 2019, respectively, and $3,001 and $3,545 during the six months ended October 24, 2020 and October 26, 2019, respectively.
The following rollforward summarizes the activity related to the DPP receivable:
10

Table of Contents

|  |  | Six Months Ended
|  |  |  |  | October 24, 2020 |  | October 26, 2019
Beginning DPP receivable balance |  |  |  |  | $ | 117,327 |  |  | $ | 57,238 |
Non-cash additions to DPP receivable |  |  |  |  | 386,159 |  |  | 205,389 |
Cash collections on DPP receivable |  |  |  |  | (335,228) |  |  | (187,066) |
Ending DPP receivable balance |  |  |  |  | $ | 168,258 |  |  | $ | 75,561 |

Note 3. Customer Financing
As a convenience to our customers, we offer several different financing alternatives, including a third party program and a Patterson-sponsored program. For the third party program, we act as a facilitator between the customer and the third party financing entity with no on-going involvement in the financing transaction. Under the Patterson-sponsored program, equipment purchased by creditworthy customers may be financed up to a maximum of $1,000. We generally sell our customers’ financing contracts to outside financial institutions in the normal course of our business. These financing arrangements are accounted for as a sale of assets under the provisions of ASC 860, Transfers and Servicing. We currently have two arrangements under which we sell these contracts. We use a monthly unit of account for these financing contracts.
First, we operate under an agreement to sell a portion of our equipment finance contracts to commercial paper conduits with MUFG serving as the agent. We utilize PDC Funding to fulfill a requirement of participating in the commercial paper conduit. We receive the proceeds of the contracts upon sale to MUFG. At least 15.0% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with MUFG. The capacity under the agreement with MUFG at October 24, 2020 was $525,000.
Second, we maintain an agreement with Fifth Third Bank ("Fifth Third") whereby Fifth Third purchases customers’ financing contracts. PDC Funding II sells its financing contracts to Fifth Third. We receive the proceeds of the contracts upon sale to Fifth Third. At least 15.0% of the proceeds are held by the conduit as security against eventual performance of the portfolio. This percentage can be greater and is based upon certain ratios defined in the agreement with Fifth Third. The capacity under the agreement with Fifth Third at October 24, 2020 was $100,000.
We service the financing contracts under both arrangements, for which we are paid a servicing fee. The servicing fees we receive are considered adequate compensation for services rendered. Accordingly, no servicing asset or liability has been recorded.
The portion of the purchase price for the receivables held by the conduits is deemed a DPP receivable, which is paid to the applicable special purpose entity as payments on the customers’ financing contracts are collected by Patterson from customers. The difference between the carrying amount of the receivables sold under these programs and the sum of the cash and fair value of the DPP receivable received at time of transfer is recognized as a gain on sale of the related receivables and recorded in net sales in the condensed consolidated statements of operations and other comprehensive income. Expenses incurred related to customer financing activities are recorded in operating expenses in our condensed consolidated statements of operations and other comprehensive income.
During the six months ended October 24, 2020 and October 26, 2019, we sold $130,258 and $101,624 of contracts under these arrangements, respectively. In net sales in the condensed consolidated statements of operations and other comprehensive income, we recorded a gain of $1,614 and $3,550 during the three months ended October 24, 2020 and October 26, 2019, respectively, related to these contracts sold. In net sales in the condensed consolidated statements of operations and other comprehensive income, we recorded a gain of $1,272 and $10,896 during the six months ended October 24, 2020 and October 26, 2019, respectively, related to these contracts sold. Cash collections on financed receivables sold were $177,193 and $181,702 during the six months ended October 24, 2020 and October 26, 2019, respectively.
Included in cash and cash equivalents in the condensed consolidated balance sheets are $43,955 and $21,830 as of October 24, 2020 and April 25, 2020, respectively, which represent cash collected from previously sold customer financing contracts that have not yet been settled. Included in current receivables in the condensed consolidated
11

Table of Contents
balance sheets are $59,328 and $21,391 as of October 24, 2020 and April 25, 2020, respectively, of finance contracts we have not yet sold. A total of $612,003 of finance contracts receivable sold under the arrangements was outstanding at October 24, 2020. Since the internal financing program began in 1994, bad debt write-offs have amounted to less than 1% of the loans originated.
The following rollforward summarizes the activity related to the DPP receivable:

|  |  |  | Six Months Ended
|  |  |  |  |  | October 24, 2020 |  | October 26, 2019
Beginning DPP receivable balance |  |  |  |  |  | $ | 228,019 |  |  | $ | 121,657 |
Non-cash additions to DPP receivable |  |  |  |  |  | 51,171 |  |  | 5,667 |
Cash collections on DPP receivable |  |  |  |  |  | (73,679) |  |  | (25,241) |
Ending DPP receivable balance |  |  |  |  |  | $ | 205,511 |  |  | $ | 102,083 |

The arrangements require us to maintain a minimum current ratio and maximum leverage ratio. We were in compliance with those covenants at October 24, 2020.
Note 4. Derivative Financial Instruments
We are a party to certain offsetting and identical interest rate cap agreements entered into to fulfill certain covenants of the equipment finance contract sale agreements. The interest rate cap agreements also provide a credit enhancement feature for the financing contracts sold by PDC Funding and PDC Funding II to the commercial paper conduit.
The interest rate cap agreements are canceled and new agreements are entered into periodically to maintain consistency with the dollar maximum of the sale agreements and the maturity of the underlying financing contracts. As of October 24, 2020, PDC Funding had purchased an interest rate cap from a bank with a notional amount of $525,000 and a maturity date of August 2028. We sold an identical interest rate cap to the same bank. As of October 24, 2020, PDC Funding II had purchased an interest rate cap from a bank with a notional amount of $100,000 and a maturity date of November 2027. We sold an identical interest rate cap to the same bank.
These interest rate cap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs.
In January 2014, we entered into a forward interest rate swap agreement with a notional amount of $250,000 and accounted for it as a cash flow hedge, in order to hedge interest rate fluctuations in anticipation of refinancing the 5.17% senior notes due March 25, 2015. These notes were repaid on March 25, 2015 and replaced with new $250,000 3.48% senior notes due March 24, 2025. A cash payment of $29,003 was made in March 2015 to settle the interest rate swap. This amount is recorded in other comprehensive income (loss), net of tax, and is recognized as interest expense over the life of the related debt.
We utilize forward interest rate swap agreements to hedge against interest rate fluctuations that impact the amount of net sales we record related to our customer financing contracts. These interest rate swap agreements do not qualify for hedge accounting treatment and, accordingly, we record the fair value of the agreements as an asset or liability and the change as income or expense during the period in which the change occurs.
As of April 25, 2020, the remaining notional amount for interest rate swap agreements was $634,029, with the latest maturity date in fiscal 2027. During the six months ended October 24, 2020, we entered into forward interest rate swap agreements with a notional amount of $125,458. As of October 24, 2020, the remaining notional amount for interest rate swap agreements was $663,114, with the latest maturity date in fiscal 2028.
Net cash payments of $5,116 and $615 were made during the six months ended October 24, 2020 and October 26, 2019, respectively, to settle a portion of our liabilities related to interest rate swap agreements. These payments are reflected as cash outflows in the condensed consolidated statements of cash flows within net cash used in operating activities.
12

Table of Contents
The following presents the fair value of derivative instruments included in the condensed consolidated balance sheets:

Derivative type | Classification | October 24, 2020 |  | April 25, 2020
Assets: |  |  |  |
Interest rate contracts | Other non-current assets | $ | 365 |  |  | $ | 204 |
Liabilities: |  |  |  |
Interest rate contracts | Other accrued liabilities | 5,160 |  |  | 6,789 |
Interest rate contracts | Other non-current liabilities | 10,513 |  |  | 13,060 |
Total liability derivatives |  | $ | 15,673 |  |  | $ | 19,849 |

The following tables present the pre-tax effect of derivative instruments on the condensed consolidated statements of operations and other comprehensive income:

|  |  |  | Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income (Effective Portion)
|  |  |  | Three Months Ended |  | Six Months Ended
Derivatives in cash flow hedging relationships |  | Statements of operations location |  | October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Interest rate contracts |  | Interest expense |  | $ | (342) |  |  | $ | (725) |  |  | $ | (682) |  |  | $ | (1,450) |

|  |  |  | Amount of Gain (Loss) Recognized in Income on Derivatives
|  |  |  | Three Months Ended |  | Six Months Ended
Derivatives not designated as hedging instruments |  | Statements of operations location |  | October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Interest rate contracts |  | Other income, net |  | $ | 415 |  |  | $ | (1,778) |  |  | $ | (780) |  |  | $ | (5,563) |

There were no gains or losses recognized in other comprehensive income (loss) on cash flow hedging derivatives during the three and six months ended October 24, 2020 or October 26, 2019.
We recorded no ineffectiveness during the three and six month periods ended October 24, 2020 and October 26, 2019. As of October 24, 2020, the estimated pre-tax portion of accumulated other comprehensive loss that is expected to be reclassified into earnings over the next twelve months is $1,363, which will be recorded as an increase to interest expense.
Note 5. Fair Value Measurements
Fair value is the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. The fair value hierarchy of measurements is categorized into one of three levels based on the lowest level of significant input used:
Level 1 - Quoted prices in active markets for identical assets and liabilities at the measurement date.
Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 - Unobservable inputs for which there is little or no market data available. These inputs reflect management’s assumptions of what market participants would use in pricing the asset or liability.
Our hierarchy for assets and liabilities measured at fair value on a recurring basis is as follows:
13

Table of Contents

| October 24, 2020
| Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |
Cash equivalents | $ | 2,269 |  |  | $ | 2,269 |  |  | $ | — |  |  | $ | — |
DPP receivable - receivables securitization program | 168,258 |  |  | — |  |  | — |  |  | 168,258 |
DPP receivable - customer financing | 205,511 |  |  | — |  |  | — |  |  | 205,511 |
Derivative instruments | 365 |  |  | — |  |  | 365 |  |  | — |
Total assets | $ | 376,403 |  |  | $ | 2,269 |  |  | $ | 365 |  |  | $ | 373,769 |
Liabilities: |  |  |  |  |  |  |
Derivative instruments | $ | 15,673 |  |  | $ | — |  |  | $ | 15,673 |  |  | $ | — |

| April 25, 2020
| Total |  | Level 1 |  | Level 2 |  | Level 3
Assets: |  |  |  |  |  |  |
Cash equivalents | $ | 3,391 |  |  | $ | 3,391 |  |  | $ | — |  |  | $ | — |
DPP receivable - receivables securitization program | 117,327 |  |  | — |  |  | — |  |  | 117,327 |
DPP receivable - customer financing | 228,019 |  |  | — |  |  | — |  |  | 228,019 |
Derivative instruments | 204 |  |  | — |  |  | 204 |  |  | — |
Total assets | $ | 348,941 |  |  | $ | 3,391 |  |  | $ | 204 |  |  | $ | 345,346 |
Liabilities: |  |  |  |  |  |  |
Derivative instruments | $ | 19,849 |  |  | $ | — |  |  | $ | 19,849 |  |  | $ | — |

Cash equivalents – We value cash equivalents at their current market rates. The carrying value of cash equivalents approximates fair value and maturities are less than three months.
DPP receivable - receivables securitization program – We value this DPP receivable based on a discounted cash flow analysis using unobservable inputs, which include the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant.
DPP receivable - customer financing – We value this DPP receivable based on a discounted cash flow analysis using unobservable inputs, which include a forward yield curve, the estimated timing of payments and the credit quality of the underlying creditor. Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant.
Derivative instruments – Our derivative instruments consist of interest rate cap agreements and interest rate swaps. These instruments are valued using inputs such as interest rates and credit spreads.
Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments under certain circumstances. We adjust the carrying value of our non-marketable equity securities to fair value when observable transactions of identical or similar securities occur, or due to an impairment.
During the six months ended October 26, 2019, we recorded a pre-tax gain of $34,334 related to one of our investments in other income, net in our condensed consolidated statements of operations and other comprehensive income. This gain was based on the selling price of preferred stock in this investment that is similar to the preferred stock we own, and was adjusted for differences in liquidation preferences. As of both October 24, 2020 and April 25, 2020, this investment had a carrying value of $51,628. There were no fair value adjustments to such assets during the six months ended October 24, 2020.
Our debt is not measured at fair value in the condensed consolidated balance sheets. The estimated fair value of our debt as of October 24, 2020 and April 25, 2020 was $612,648 and $601,856, respectively, as compared to a carrying value of $588,329 and $587,766 at October 24, 2020 and April 25, 2020, respectively. The fair value of debt was measured using a discounted cash flow analysis based on expected market based yields (i.e., Level 2 inputs).
14

Table of Contents
The carrying amounts of receivables, net of allowances, accounts payable, and certain accrued and other current liabilities approximated fair value at October 24, 2020 and April 25, 2020.
Note 6. Income Taxes
The effective income tax rate for the three months ended October 24, 2020 was 23.7%. For the three months ended October 26, 2019, income tax expense was $6,426 on a loss before taxes of $26,923. The effective income tax rate for the six months ended October 24, 2020 was 24.8%. For the six months ended October 26, 2019, income tax expense was $16,520 on income before taxes of $12,978, for an effective income tax rate of 127.3%. Income tax expense for the three and six months ended October 26, 2019 was adversely impacted by the Fiscal 2020 U.S. Attorney's Office Legal Reserve, as these costs and expenses were not fully deductible.
Note 7. Technology Partner Innovations, LLC ("TPI")
In fiscal 2019, we entered into an agreement with Cure Partners to form TPI, which offers a cloud-based practice management software, NaVetor, to its customers. Patterson and Cure Partners each contributed net assets of $4,000 to form TPI. We determined that TPI is a variable interest entity, and we consolidate the results of operations of TPI as we have concluded that we are the primary beneficiary of TPI. During the three months ended October 24, 2020 and October 26, 2019, net loss attributable to the noncontrolling interest was $234 and $220, respectively. During the six months ended October 24, 2020 and October 26, 2019, net loss attributable to the noncontrolling interest was $439 and $455, respectively, resulting in noncontrolling interests of $1,888 on the condensed consolidated balance sheets at October 24, 2020.
Note 8. Segment and Geographic Data
We present three reportable segments: Dental, Animal Health and Corporate. Dental and Animal Health are strategic business units that offer similar products and services to different customer bases. Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists, dental laboratories, institutions, and other healthcare professionals throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results. Corporate assets consist primarily of cash and cash equivalents, accounts receivable, property and equipment and long-term receivables. We evaluate segment performance based on operating income. The costs to operate the fulfillment centers are allocated to the operating units based on the through-put of the unit.
The following tables present information about our reportable segments:
15

Table of Contents

| Three Months Ended |  | Six Months Ended
| October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Consolidated net sales |  |  |  |  |  |  |
United States | $ | 1,279,106 |  |  | $ | 1,183,047 |  |  | $ | 2,313,978 |  |  | $ | 2,273,762 |
United Kingdom | 179,695 |  |  | 153,404 |  |  | 329,087 |  |  | 302,818 |
Canada | 94,367 |  |  | 82,293 |  |  | 155,940 |  |  | 170,815 |
Total | $ | 1,553,168 |  |  | $ | 1,418,744 |  |  | $ | 2,799,005 |  |  | $ | 2,747,395 |
Dental net sales |  |  |  |  |  |  |
United States | $ | 570,769 |  |  | $ | 513,141 |  |  | $ | 968,229 |  |  | $ | 957,783 |
Canada | 60,979 |  |  | 51,462 |  |  | 93,814 |  |  | 107,956 |
Total | $ | 631,748 |  |  | $ | 564,603 |  |  | $ | 1,062,043 |  |  | $ | 1,065,739 |
Animal Health net sales |  |  |  |  |  |  |
United States | $ | 701,094 |  |  | $ | 663,953 |  |  | $ | 1,335,117 |  |  | $ | 1,300,050 |
United Kingdom | 179,695 |  |  | 153,404 |  |  | 329,087 |  |  | 302,818 |
Canada | 33,388 |  |  | 30,831 |  |  | 62,126 |  |  | 62,859 |
Total | $ | 914,177 |  |  | $ | 848,188 |  |  | $ | 1,726,330 |  |  | $ | 1,665,727 |
Corporate net sales |  |  |  |  |  |  |
United States | $ | 7,243 |  |  | $ | 5,953 |  |  | $ | 10,632 |  |  | $ | 15,929 |
Total | $ | 7,243 |  |  | $ | 5,953 |  |  | $ | 10,632 |  |  | $ | 15,929 |

16

Table of Contents

| Three Months Ended |  | Six Months Ended
| October 24, 2020 |  | October 26, 2019 1 |  | October 24, 2020 |  | October 26, 2019 1
Consolidated net sales |  |  |  |  |  |  |
Consumable | $ | 1,241,586 |  |  | $ | 1,127,481 |  |  | $ | 2,286,567 |  |  | $ | 2,222,665 |
Equipment and software | 220,181 |  |  | 205,790 |  |  | 349,558 |  |  | 348,323 |
Value-added services and other | 91,401 |  |  | 85,473 |  |  | 162,880 |  |  | 176,407 |
Total | $ | 1,553,168 |  |  | $ | 1,418,744 |  |  | $ | 2,799,005 |  |  | $ | 2,747,395 |
Dental net sales |  |  |  |  |  |  |
Consumable | $ | 357,849 |  |  | $ | 304,565 |  |  | $ | 614,452 |  |  | $ | 608,039 |
Equipment and software | 198,135 |  |  | 188,192 |  |  | 311,098 |  |  | 313,876 |
Value-added services and other | 75,764 |  |  | 71,846 |  |  | 136,493 |  |  | 143,824 |
Total | $ | 631,748 |  |  | $ | 564,603 |  |  | $ | 1,062,043 |  |  | $ | 1,065,739 |
Animal Health net sales |  |  |  |  |  |  |
Consumable | $ | 883,737 |  |  | $ | 822,916 |  |  | $ | 1,672,115 |  |  | $ | 1,614,626 |
Equipment and software | 22,046 |  |  | 17,598 |  |  | 38,460 |  |  | 34,447 |
Value-added services and other | 8,394 |  |  | 7,674 |  |  | 15,755 |  |  | 16,654 |
Total | $ | 914,177 |  |  | $ | 848,188 |  |  | $ | 1,726,330 |  |  | $ | 1,665,727 |
Corporate net sales |  |  |  |  |  |  |
Value-added services and other | $ | 7,243 |  |  | $ | 5,953 |  |  | $ | 10,632 |  |  | $ | 15,929 |
Total | $ | 7,243 |  |  | $ | 5,953 |  |  | $ | 10,632 |  |  | $ | 15,929 |

1 Certain sales were reclassified between categories to conform to the current period presentation.

| Three Months Ended |  | Six Months Ended
| October 24, 2020 |  | October 26, 2019 |  | October 24, 2020 |  | October 26, 2019
Operating income (loss) |  |  |  |  |  |  |
Dental | $ | 72,957 |  |  | $ | 52,632 |  |  | $ | 110,726 |  |  | $ | 86,636 |
Animal Health | 17,591 |  |  | 18,174 |  |  | 34,990 |  |  | 37,798 |
Corporate | (16,842) |  |  | (88,952) |  |  | (34,138) |  |  | (125,906) |
Consolidated operating income (loss) | $ | 73,706 |  |  | $ | (18,146) |  |  | $ | 111,578 |  |  | $ | (1,472) |

| October 24, 2020 |  | April 25, 2020
Total assets |  |  |
Dental | $ | 790,788 |  |  | $ | 704,216 |
Animal Health | 1,445,853 |  |  | 1,485,284 |
Corporate | 552,383 |  |  | 525,850 |
Total assets | $ | 2,789,024 |  |  | $ | 2,715,350 |

Note 9. Accumulated Other Comprehensive Loss ("AOCL")
The following table summarizes the changes in AOCL as of October 24, 2020:
17

Table of Contents

| Cash Flow Hedges |  | Currency Translation Adjustment |  | Total
AOCL at April 25, 2020 | $ | (5,538) |  |  | $ | (91,501) |  |  | $ | (97,039) |
Other comprehensive loss before reclassifications | — |  |  | 15,916 |  |  | 15,916 |
Amounts reclassified from AOCL | 521 |  |  | — |  |  | 521 |
AOCL at October 24, 2020 | $ | (5,017) |  |  | $ | (75,585) |  |  | $ | (80,602) |

The amounts reclassified from AOCL during the six months ended October 24, 2020 include gains and losses on cash flow hedges, net of taxes of $161. The impact to the condensed consolidated statements of operations and other comprehensive income was an increase to interest expense of $682 for the six months ended October 24, 2020.
Note 10. Legal Proceedings
From time to time, we become involved in lawsuits, administrative proceedings, government subpoenas, and government investigations (which may, in some cases, involve our entering into settlement agreements or consent decrees), relating to antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, securities, and other matters, including matters arising out of the ordinary course of business. The results of any such proceedings cannot be predicted with certainty because such matters are inherently uncertain. Significant damages or penalties may be sought in some matters, and some matters may require years to resolve. We also may be subject to fines or penalties, and equitable remedies (including but not limited to the suspension, revocation or non-renewal of licenses).
We accrue for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Unless otherwise noted, with respect to the specific legal proceedings and claims described below, the amount or range or possible losses is not reasonably estimable. Adverse outcomes in some or all of these matters may result in significant monetary damages or injunctive relief against us that could adversely affect our ability to conduct our business. There also exists the possibility of a material adverse effect on our financial statements for the period in which the effect of an unfavorable outcome becomes probable and reasonably estimable.
On March 28, 2018, Plymouth County Retirement System (“Plymouth”) filed a federal securities class action complaint against Patterson Companies, Inc. and its former CEO Scott P. Anderson and former CFO Ann B. Gugino in the U.S. District Court for the District of Minnesota in a case captioned Plymouth County Retirement System v. Patterson Companies, Inc., Scott P. Anderson and Ann B. Gugino, Case No. 0:18-cv-00871 MJD/SER. On November 9, 2018, the complaint was amended to add former CEO James W. Wiltz and former CFO R. Stephen Armstrong as individual defendants. Under the amended complaint, on behalf of all persons or entities that purchased or otherwise acquired Patterson’s common stock between June 26, 2013 and February 28, 2018, Plymouth alleges that Patterson violated federal securities laws by failing to disclose that Patterson’s revenue and earnings were “artificially inflated by Defendants’ illicit, anti-competitive scheme with its purported competitors, Benco and Schein, to prevent the formation of buying groups that would allow its customers who were office-based practitioners to take advantage of pricing arrangements identical or comparable to those enjoyed by large-group customers.” In its class action complaint, Plymouth asserts one count against Patterson for violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and a second, related count against the individual defendants for violating Section 20(a) of the Exchange Act. Plymouth seeks compensatory damages, pre- and post-judgment interest and reasonable attorneys’ fees and experts’ witness fees and costs. On August 30, 2018, Gwinnett County Public Employees Retirement System and Plymouth County Retirement System, Pembroke Pines Pension Fund for Firefighters and Police Officers, Central Laborers Pension Fund were appointed lead plaintiffs. On January 18, 2019, Patterson and the individual defendants filed a motion to dismiss the amended complaint. On July 25, 2019, the U.S. Magistrate Judge issued a report and recommendation that the motion to dismiss be granted in part and denied in part. The report and recommendation, among other things, recommends the dismissal of all claims against individual defendants Ann B. Gugino, R. Stephen Armstrong and James W. Wiltz. On September 10, 2019, the District Court adopted the Magistrate Judge’s report and recommendation. On September 28, 2020, the District Court granted plaintiffs’ motion to certify the class, appoint class representatives and appoint class counsel. On October 12, 2020, Patterson and the remaining individual defendant, Mr. Anderson, filed a Rule 23(f) petition for interlocutory appeal of the class certification order with the Eighth Circuit Court of Appeals in which the defendants sought clarification of the standard for rebutting the Basic presumption of class-wide reliance in securities class actions. On October 13, 2020, Patterson and Mr. Anderson filed a motion to stay
18

Table of Contents
the underlying proceeding with the District Court pending the possibility of interlocutory appeal. On November 9, 2020, the District Court denied defendants’ motion to stay and on November 12, 2020, the Eighth Circuit Court of Appeals denied defendants’ Rule 23(f) petition. While the outcome of litigation is inherently uncertain, we believe that the class action complaint is without merit, and we are vigorously defending ourselves in this litigation. We do not anticipate that this matter will have a material adverse effect on our financial statements. Patterson has also received, and responded to, requests under Minnesota Business Corporation Act § 302A.461 to inspect corporate books and records relating to the issues raised in the securities class action complaint and certain antitrust litigation.
On October 1, 2018, Sally Pemberton filed a stockholder derivative complaint against Patterson Companies, Inc., as a nominal defendant, and the following former and current officers and directors of Patterson: Scott Anderson, Ann Gugino, Mark Walchirk, John Buck, Alex Blanco, Jody Feragen, Sarena Lin, Ellen Rudnick, Neil Schrimsher, Les Vinney, James Wiltz, Paul Guggenheim, David Misiak and Tim Rogan as individual defendants in the U.S. District Court for the District of Minnesota in a case captioned Sally Pemberton v. Scott P. Anderson, et al., Case No. 18-CV-2818 (PJS/HB). Derivatively on behalf of Patterson, plaintiff alleges that Patterson, with Benco and Henry Schein, “engage[d] in a conspiracy in restraint of trade, whereby the companies agreed to refuse to offer discounted prices or otherwise negotiate with GPOs, agreed to fix margins on dental supplies and equipment, agreed not to poach one another’s customers or sales representatives, and agreed to block the entry and expansion of rival distributors." Plaintiff further alleges that the individual defendants failed to disclose Patterson’s alleged “antitrust misconduct” to the public and purportedly caused Patterson to repurchase $412,800 of its own stock at prices that were artificially inflated. In the derivative complaint, plaintiff asserts six counts against the individual defendants for: (i) breach of fiduciary duty; (ii) waste of corporate assets; (iii) unjust enrichment; (iv) violations of Section 14(a) of the Exchange Act; (v) violations of Section 10(b) and Rule 10b-5 of the Exchange Act and (vi) violations of Section 20(a) of the Exchange Act. Plaintiff seeks compensatory damages with pre-judgment and post-judgment interest, costs, disbursements and reasonable attorneys’ fees, experts’ fees, costs and expenses, and an order awarding restitution from the individual defendants and directing Patterson “to take all necessary actions to reform and improve its corporate governance and internal procedures.” On September 10, 2019, the Honorable Patrick J. Schiltz dismissed this action without prejudice because the plaintiff failed to make a pre-suit demand on Patterson’s Board of Directors. On October 31, 2019, Patterson’s Board received a written demand to initiate litigation against its officers and directors based on the claims Ms. Pemberton originally presented in her complaint. Following this demand, and after consultation with legal counsel, effective March 16, 2020, the Board adopted a resolution appointing Professor John Matheson and The Honorable George McGunnigle, retired Judge of Hennepin County District Court, as a special litigation committee pursuant to Minnesota Statutes Section 302A.241. Pursuant to the resolution, the special litigation committee has complete power and authority to investigate the demand, analyze the legal rights or remedies of Patterson, determine whether those rights or remedies should be pursued, and respond to Ms. Pemberton on behalf of Patterson.
On August 28, 2018, Kirsten Johnsen filed a stockholder derivative complaint against Patterson Companies, Inc., as a nominal defendant, and the following former and current officers and directors of Patterson: Scott Anderson, Ann Gugino, James Wiltz, John Buck, Jody Feragen, Ellen Rudnick, Les Vinney, Neil Schrimsher, Sarena Lin, Harold Slavkin, Alex Blanco and Mark Walchirk as individual defendants in Hennepin County District Court in a case captioned Kirsten Johnsen v. Scott P. Anderson et al., Case No. 27-CV-18-14315. Derivatively on behalf of Patterson, plaintiff alleges that Patterson “suppressed price competition and maintained supracompetitive prices for dental supplies and equipment by entering into agreements with Henry Schein and Benco to: (i) fix margins for dental supplies and equipment; and (ii) block the entry and expansion of lower-margin, lower-priced, rival dental distributors through threatened and actual group boycotts.” Plaintiff further alleges that the individual defendants failed to disclose Patterson’s alleged “price-fixing scheme” to the public and purportedly “caused Patterson to repurchase over $412,800 worth of its own stock at artificially inflated prices.” In the derivative complaint, plaintiff asserts three counts against the individual defendants for: (i) breach of fiduciary duty; (ii) waste of corporate assets; and (iii) unjust enrichment. Plaintiff seeks compensatory damages, equitable and injunctive relief as permitted by law, costs, disbursements and reasonable attorneys’ fees, accountants’ fees and experts’ fees, costs and expenses, and an order awarding restitution from the individual defendants and directing Patterson “to take all necessary actions to reform and improve its corporate governance and internal procedures.” On February 19, 2019, the Hennepin County District Court ordered this litigation stayed pending resolution of the above-described case brought by Sally Pemberton. On September 10, 2019, the Honorable Patrick J. Schiltz dismissed Pemberton without prejudice because the plaintiff failed to make a pre-suit demand on Patterson’s Board of Directors. On November 5, 2019, the defendants in Johnsen moved to dismiss such action based on plaintiff’s failure to make a pre-suit demand or otherwise properly plead demand futility. On December 12, 2019, in light of the outcome in Pemberton, the defendants and Johnsen entered into a stipulation for voluntary dismissal of the Johnsen action, which the court granted on December 13, 2019. On April 27, 2020, Patterson’s Board received a written demand to
19

Table of Contents
initiate litigation against its officers and directors based on the claims Ms. Johnsen originally presented in her complaint. Effective June 30, 2020, the Board adopted a resolution expanding the scope of the previously constituted special litigation committee to include this matter. Pursuant to the resolution, the special litigation committee has complete power and authority to investigate the demand, analyze the legal rights or remedies of Patterson, determine whether those rights or remedies should be pursued, and respond to Ms. Johnsen on behalf of Patterson.
On October 27, 2020, Patterson’s Board received a written demand from Matthew Davis to undertake an independent investigation and take action to remedy alleged breaches of fiduciary duties by the following current and former directors and officers of Patterson: John Buck, Scott Anderson, Stephen Armstrong, Ann Gugino, Mark Walchirk, Alex Blanco, Jody Feragen, Sarena Lin, Ellen Rudnick, Neil Schrimsher, Les Vinney, James Wiltz, Paul Guggenheim, David Misiak, Harold Slavkin and Tim Rogan. The demand arises from the allegations that Patterson (a) conspired with Henry Schein and Benco over a multi-year period to boycott GPOs and fix dental supply prices; and (b) issued a series of materially false and misleading statements in connection with such scheme. The demand seeks the institution of an action for breach of fiduciary duty and appropriate remedial measures, including obtaining damages from all persons unjustly enriched. Effective November 20, 2020, Patterson’s Board adopted a resolution expanding the scope of the previously constituted special litigation committee to include this matter. Pursuant to the resolution, the special litigation committee has complete power and authority to investigate the demand, analyze the legal rights or remedies of Patterson, determine whether those rights or remedies should be pursued, and respond to Mr. Davis on behalf of Patterson.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
The U.S. Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements to encourage companies to provide prospective information, so long as those statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those disclosed in the statement.
This Form 10-Q contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, and the objectives and expectations of management. Forward-looking statements often include words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “seeks” or words of similar meaning, or future or conditional verbs, such as “will,” “should,” “could” or “may.” Forward-looking statements are neither historical facts nor assurances of future performance. Instead, such statements, including, but not limited to, our statements regarding business strategy, growth strategy, competitive strengths, productivity and profitability enhancement, competition, new product and service introductions and liquidity and capital resources, are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, as well as on assumptions made by and information currently available to management, and involve various risks and uncertainties, some of which are beyond our control.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.
Any number of factors could affect our actual results and cause such results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the following: the effects of the highly competitive dental and animal health supply markets in which we compete; the COVID-19 pandemic and measures taken in response thereto; general economic conditions, including political and economic uncertainty; risks from disruption to our information systems; our ability to comply with restrictive covenants in our amended credit agreement; our dependence on relationships with sales representatives, service technicians and customers; our ability to realize the long-term strategic benefits of our acquisition of Animal Health International; potential disruption of distribution capabilities, including service issues with third-party shippers; our ability to provide our sales force and customers with the latest technology; our dependence on suppliers for the manufacture and supply of the
20

Table of Contents
products we sell; material changes in our purchasing relationship with suppliers; the risk that private label sales could adversely affect our relationships with suppliers; our dependence on positive perceptions of Patterson’s reputation; risks inherent in acquiring other businesses; the risk that our acquired technology or developed technology might not be successful in maintaining or gaining customers; litigation risks, including new or unanticipated litigation developments and new or unanticipated regulatory investigations; changes in consumer preferences; regulatory restrictions; the cyclicality of the livestock market; the outbreak of an infectious disease within the production animal or companion animal population; pressure from animal rights groups; adverse changes in supplier rebates; fluctuations in quarterly financial results; volatility in the price of our stock; risks from the expansion of customer purchasing power; increases in over-the-counter sales of companion animal products; the risks inherent in international operations, including currency fluctuations; the effects of health care reform; failure to comply with regulatory requirements and data privacy laws; cyberattacks or other privacy or data security breaches; the risk of the products we sell becoming obsolete or containing undetected errors; volatility in the financial markets; our dependence on our senior management; our dependence on leadership development and succession planning; disruptions from our enterprise resource planning system; risks associated with shareholder activism; the risk of being required to record impairment charges; the risk of audit by tax authorities; risks associated with interest rate fluctuations; and the risk that our governing documents and Minnesota law may discourage takeovers and business combinations. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive, accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results.
You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in our most recent Form 10-K, and information which may be contained in our other filings with the U.S. Securities and Exchange Commission, or SEC, when reviewing any forward-looking statement. In light of these risks and uncertainties, there can be no assurance that the forward-looking information will in fact prove to be accurate. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in our SEC filings, to be a complete discussion of all potential risks or uncertainties.
Any forward-looking statement made in this Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We do not undertake any obligation to release publicly any revisions to any forward-looking statements whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
OVERVIEW
Our financial information for the first six months of fiscal 2021 is summarized in this Management’s Discussion and Analysis and the Condensed Consolidated Financial Statements and related Notes. The following background is provided to readers to assist in the review of our financial information.
We present three reportable segments: Dental, Animal Health and Corporate. Dental and Animal Health are strategic business units that offer similar products and services to different customer bases. Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists and dental laboratories throughout North America. Animal Health is a leading, full-line distributor in North America and the U.K. of animal health products, services and technologies to both the production-animal and companion-pet markets. Our Corporate segment is comprised of general and administrative expenses, including home office support costs in areas such as information technology, finance, legal, human resources and facilities. In addition, customer financing and other miscellaneous sales are reported within Corporate results.
Operating margins of the animal health business are considerably lower than the dental business. While operating expenses run at a lower rate in the animal health business when compared to the dental business, gross margins in the animal health business are substantially lower due generally to the low margins experienced on the sale of pharmaceutical products.
We operate with a 52-53 week accounting convention with our fiscal year ending on the last Saturday in April. The second quarter of fiscal 2021 and 2020 represents the 13 weeks ended October 24, 2020 and the 13 weeks ended October 26, 2019, respectively. The six months ended October 24, 2020 and October 26, 2019 each included 26 weeks. Fiscal 2021 will include 52 weeks and fiscal 2020 included 52 weeks.
21

Table of Contents
We believe there are several important aspects of our business that are useful in analyzing it, including: (1) growth in the various markets in which we operate; (2) internal growth; (3) growth through acquisition; and (4) continued focus on controlling costs and enhancing efficiency. Management defines internal growth as the increase in net sales from period to period, adjusting for differences in the number of weeks in fiscal years, excluding the impact of changes in currency exchange rates, and excluding the net sales, for a period of twelve months following the transaction date, of businesses we have acquired.
FACTORS AFFECTING OUR RESULTS
COVID-19. The COVID-19 pandemic, including closures and other steps taken by governmental authorities in response to the virus, has had a significant impact on our businesses. As part of our broad-based effort to respond to the COVID-19 pandemic, we implemented cost reduction measures, including temporary salary reductions, furloughs and reduced work hours across our workforce during the period from May 1, 2020 through July 31, 2020. Within our Dental segment, the effect became less significant during the quarter ended July 25, 2020, as dental offices began opening for elective procedures. In addition, we did record increased sales of infection control products during the three and six months ended October 24, 2020 within the Dental segment. The disruptions we experienced in our production animal business as a result of the pandemic became less significant during the three months ended October 24, 2020.
Gain on Investment. We recorded a pre-tax gain of $34.3 million related to one of our investments ("Gain on Investment") during the first quarter of fiscal 2020. This gain was based on the selling price of preferred stock in this investment that is similar to the preferred stock we own, and was adjusted for differences in liquidation preferences.
Fiscal 2020 U.S. Attorney's Office Legal Reserve. We incurred costs and expenses of $58.3 million ("Fiscal 2020 U.S. Attorney's Office Legal Reserve") during the second quarter of fiscal 2020 related to the then-probable settlement of litigation with the U.S. Attorney's Office for the Western District of Virginia, which were recorded within operating expenses in the condensed consolidated statements of operations and other comprehensive income in our Corporate segment.
Fiscal 2020 SourceOne Dental Legal Reserve. We incurred expenses of $17.7 million ("Fiscal 2020 SourceOne Dental Legal Reserve") during the first quarter of fiscal 2020 related to the settlement of litigation with SourceOne Dental, Inc., which were recorded within operating expenses in the condensed consolidated statements of operations and other comprehensive income in our Corporate segment.
Receivables Securitization Program. We are a party to certain receivables purchase agreements with MUFG Bank, Ltd. ("MUFG"), under which MUFG acts as an agent to facilitate the sale of certain Patterson receivables (the “Receivables”) to certain unaffiliated financial institutions (the “Purchasers”). The proceeds from the sale of these Receivables comprise a combination of cash and a deferred purchase price (“DPP”) receivable. The DPP receivable is ultimately realized by Patterson following the collection of the underlying Receivables sold to the Purchasers. The collection of the DPP receivable is recognized as an increase to net cash provided by investing activities within the condensed consolidated statements of cash flows, with a corresponding reduction to net cash used in operating activities within the condensed consolidated statements of cash flows.
RESULTS OF OPERATIONS
QUARTER ENDED OCTOBER 24, 2020 COMPARED TO QUARTER ENDED OCTOBER 26, 2019
The following table summarizes our results as a percent of net sales:
22

Table of Contents

| Three Months Ended
| October 24, 2020 |  | October 26, 2019
Net sales | 100.0 | % |  | 100.0 | %
Cost of sales | 79.4 |  |  | 78.7 |
Gross profit | 20.6 |  |  | 21.3 |
Operating expenses | 15.9 |  |  | 22.6 |
Operating income (loss) | 4.7 |  |  | (1.3) |
Other income (expense) | (0.2) |  |  | (0.6) |
Income (loss) before taxes | 4.5 |  |  | (1.9) |
Income tax expense | 1.0 |  |  | 0.5 |
Net income (loss) | 3.5 |  |  | (2.4) |
Net loss attributable to noncontrolling interests | — |  |  | — |
Net income (loss) attributable to Patterson Companies, Inc. | 3.5 | % |  | (2.4) | %

Net Sales. Consolidated net sales for the three months ended October 24, 2020 were $1,553.2 million, an increase of 9.5% from $1,418.7 million for the three months ended October 26, 2019. Foreign exchange rate changes had a favorable impact of 0.5% on current quarter sales.
Dental segment sales for the three months ended October 24, 2020 were $631.7 million, an increase of 11.9% from $564.6 million for the three months ended October 26, 2019. Foreign exchange rate changes had an unfavorable impact of 0.2% on current quarter sales. Current quarter sales of consumables increased 17.5%, sales of dental equipment and software increased 5.3%, and sales of value-added services and other increased 5.5%. We recorded increased sales of infection control products during the three months ended October 24, 2020 within consumable sales.
Animal Health segment sales for the three months ended October 24, 2020 were $914.2 million, an increase of 7.8% from $848.2 million for the three months ended October 26, 2019. Foreign exchange rate changes had a favorable impact of 0.9% on current quarter sales. Sales were higher during the three months ended October 24, 2020, driven primarily by increased sales in our companion animal business.
Gross Profit. The consolidated gross profit margin rate for the three months ended October 24, 2020 decreased 90 basis points to 20.6%, driven by lower gross profit margins in each of our segments. The decline in our Animal Health segment gross profit rate was driven by lower transactional margins and lower rebate achievement as compared to the quarter ended October 26, 2019, and the decline in our Dental segment gross profit rate was driven by increased freight and delivery costs related to COVID-19.
Operating Expenses. Consolidated operating expenses for the three months ended October 24, 2020 were $246.7 million, a 22.8% decrease from the prior year quarter of $319.6 million. We incurred lower operating expenses during the three months ended October 24, 2020 primarily as a result of lower legal fees and settlements and travel expenses. The consolidated operating expense ratio of 15.9% decreased 670 basis points from the prior year quarter, which was also driven primarily by these same factors.
Operating Income (Loss). For the three months ended October 24, 2020, operating income was $73.7 million, or 4.7% of net sales, as compared to an operating loss of $18.1 million, or 1.3% of net sales for the three months ended October 26, 2019. The increase in operating income was primarily due to higher net sales and lower operating expenses during the three months ended October 24, 2020.
Dental segment operating income was $73.0 million for the three months ended October 24, 2020, an increase of $20.3 million from the prior year quarter. The increase was driven by higher net sales during the three months ended October 24, 2020.
Animal Health segment operating income was $17.6 million for the three months ended October 24, 2020, a decrease of $0.6 million from the prior year quarter. The decrease was primarily driven by lower gross margins.
23

Table of Contents
Corporate segment operating loss was $16.8 million and $89.0 million for the three months ended October 24, 2020 and October 26, 2019, respectively. The change was primarily driven by lower legal fees and settlements during the three months ended October 24, 2020.
Other Income (Expense). Net other expense for the three months ended October 24, 2020 was $3.2 million, compared to $8.8 million for the three months ended October 26, 2019. The improvement was primarily due to lower interest expense during the three months ended October 24, 2020. In addition, we recorded a gain on our interest rate swaps during the three months ended October 24, 2020, as opposed to a loss during the three months ended October 26, 2019.
Income Tax Expense. The effective income tax rate for the three months ended October 24, 2020 was 23.7%. For the three months ended October 26, 2019, income tax expense was $6,426 on a loss before taxes of $26,923. Income tax expense for the three months ended October 26, 2019 was adversely impacted by the Fiscal 2020 U.S. Attorney's Office Legal Reserve, as these costs and expenses were not fully deductible.
Net Income (Loss) Attributable to Patterson Companies Inc. and Earnings (Loss) Per Share. Net income attributable to Patterson Companies Inc. for the three months ended October 24, 2020 was $54.1 million, compared to a net loss attributable to Patterson Companies Inc. of $33.1 million for the three months ended October 26, 2019. Earnings (loss) per diluted share were $0.56 in the current quarter compared to $(0.35) in the prior year quarter. Weighted average diluted shares outstanding in the current quarter were 96.4 million, compared to 94.1 million in the prior year quarter. The current quarter and prior year quarter cash dividend declared was $0.26 per common share.
SIX MONTHS ENDED OCTOBER 24, 2020 COMPARED TO SIX MONTHS ENDED OCTOBER 26, 2019
The following table summarizes our results as a percent of net sales:

| Six Months Ended
| October 24, 2020 |  | October 26, 2019
Net sales | 100.0 | % |  | 100.0 | %
Cost of sales | 79.5 |  |  | 78.5 |
Gross profit | 20.5 |  |  | 21.5 |
Operating expenses | 16.5 |  |  | 21.6 |
Operating income (loss) | 4.0 |  |  | (0.1) |
Other income (expense) | (0.3) |  |  | 0.6 |
Income (loss) before taxes | 3.7 |  |  | 0.5 |
Income tax expense | 0.9 |  |  | 0.6 |
Net income (loss) | 2.8 |  |  | (0.1) |
Net loss attributable to noncontrolling interests | — |  |  | — |
Net income (loss) attributable to Patterson Companies, Inc. | 2.8 | % |  | (0.1) | %

Net Sales. Consolidated net sales for the six months ended October 24, 2020 were $2,799.0 million, a 1.9% increase from $2,747.4 million for the six months ended October 26, 2019. Foreign exchange rate changes had a favorable impact of 0.1% on current period sales.
Dental segment sales for the six months ended October 24, 2020 were $1,062.0 million, a 0.3% decrease from $1,065.7 million for the six months ended October 26, 2019. Foreign exchange rate changes had an unfavorable impact of 0.1% on current period sales. Current period sales of consumables increased 1.1%, sales of dental equipment and software decreased 0.9% to $311.1 million, and sales of value-added services and other decreased 5.1% for the six months ended October 24, 2020. While Dental segment sales were negatively affected by the COVID-19 pandemic during the six months ended October 24, 2020, we did record increased sales of infection control products during the six months ended October 24, 2020 within consumable sales.
24

Table of Contents
Animal Health segment sales for the six months ended October 24, 2020 were $1,726.3 million, a 3.6% increase from $1,665.7 million for the six months ended October 26, 2019. Foreign exchange rate changes had a favorable impact of 0.2% on current period sales.
Gross Profit. The consolidated gross profit margin rate for the six months ended October 24, 2020 decreased 100 basis points from the prior year period to 20.5%, driven by lower gross profit margins in each of our segments. The decline in our Animal Health segment gross profit rate was driven by lower transactional margins and lower rebate achievement as compared to the six months ended October 26, 2019, and the decline in our Dental segment gross profit rate was driven by increased freight and delivery costs related to COVID-19.
Operating Expenses. Consolidated operating expenses for the six months ended October 24, 2020 were $462.6 million, a 22.0% decrease from the prior year period of $593.0 million. We incurred lower operating expenses during the six months ended October 24, 2020 primarily as a result of lower legal fees and settlements, personnel costs and travel expenses. Lower personnel costs were driven by our implementation of temporary salary reductions, furloughs and reduced work hours across our workforce during the period from May 1, 2020 through July 31, 2020. The consolidated operating expense ratio of 16.5% decreased 510 basis points from the prior year period, which was also driven by these same factors.
Operating Income (Loss). For the six months ended October 24, 2020, operating income was $111.6 million, or 4.0% of net sales, as compared to an operating loss of $1.5 million, or 0.1% of net sales for the six months ended October 26, 2019. The increase in operating income was primarily due to lower legal reserve expenses and lower personnel costs incurred in the six months ended October 26, 2020, partially offset by lower gross margins.
Dental segment operating income was $110.7 million for the six months ended October 24, 2020, an increase of $24.1 million from the prior year period. The increase was primarily driven by lower personnel costs during the six months ended October 24, 2020, partially offset by lower gross margins.
Animal Health segment operating income was $35.0 million for the six months ended October 24, 2020, a decrease of $2.8 million from the prior year period. The decrease was primarily driven by lower gross margins, partially offset by lower operating expenses.
Corporate segment operating loss was $34.1 million and $125.9 million for the six months ended October 24, 2020 and October 26, 2019, respectively. The change was driven primarily by lower legal fees and settlements during the six months ended October 24, 2020.
Other Income (Expense). Net other expense for the six months ended October 24, 2020 was $7.8 million, compared to net other income of $14.5 million for the six months ended October 26, 2019. The difference in other income (expense) was primarily driven by the Gain on Investment recorded during the six months ended six months ended October 26, 2019, partially offset by a lower loss on interest rate swap agreements during the six months ended October 24, 2020, as well as lower interest expense during the six months ended October 24, 2020.
Income Tax Expense. The effective income tax rate for the six months ended October 24, 2020 was 24.8%. For the six months ended October 26, 2019, income tax expense was $16,520 on income before taxes of $12,978, for an effective income tax rate of 127.3%. Income tax expense for the six months ended October 26, 2019 was adversely impacted by the Fiscal 2020 U.S. Attorney's Office Legal Reserve, as these costs and expenses were not fully deductible.
Net Income (Loss) Attributable to Patterson Companies Inc. and Earnings (Loss) Per Share. Net income attributable to Patterson Companies Inc. for the six months ended October 24, 2020 was $78.5 million, compared to a net loss attributable to Patterson Companies Inc. of $3.1 million for the six months ended October 26, 2019. Earnings (loss) per diluted share were $0.82 in the current period compared to $(0.03) in the prior year period. Weighted average diluted shares outstanding in the current period were 96.1 million, compared to 93.9 million in the prior year period. The current period and prior year period cash dividend declared was $0.52 per common share.
LIQUIDITY AND CAPITAL RESOURCES
We are a party to certain receivables purchase agreements with MUFG Bank, Ltd. ("MUFG"), under which MUFG acts as an agent to facilitate the sale of certain Patterson receivables (the “Receivables”) to certain unaffiliated financial institutions (the “Purchasers”). The proceeds from the sale of these Receivables comprise a combination of
25

Table of Contents
cash and a deferred purchase price (“DPP”) receivable. The DPP receivable is ultimately realized by Patterson following the collection of the underlying Receivables sold to the Purchasers. The collection of the DPP receivable is recognized as an increase to net cash provided by investing activities within the condensed consolidated statements of cash flows, with a corresponding reduction to net cash used in operating activities within the condensed consolidated statements of cash flows.
Net cash used in operating activities was $423.0 million and $14.7 million for the six months ended October 24, 2020 and October 26, 2019, respectively. Net cash used in operating activities for the six months ended October 24, 2020 was primarily due to the impact of our Receivables Securitization Program, a decrease in accounts payable and an increase in accounts receivable, partially offset by a reduction in inventory.
Net cash provided by investing activities was $394.9 million and $189.5 million for the six months ended October 24, 2020 and October 26, 2019, respectively. Collections of DPP receivables were $408.9 million and $212.3 million for the six months ended October 24, 2020 and October 26, 2019, respectively. Capital expenditures were $14.4 million and $22.9 million during the six months ended October 24, 2020 and October 26, 2019, respectively. We expect to use a total of approximately $50.0 million for capital expenditures in fiscal 2021.
Net cash provided by financing activities for the six months ended October 24, 2020 was $86.6 million, driven primarily by $111.0 million attributed to draws on our revolving line of credit. We paid dividends of $25.0 million during the six months ended October 24, 2020. During the six months ended October 24, 2020, we declared cash dividends totaling $0.52 per common share. For the six months ended October 26, 2019, net cash used in financing activities was $141.7 million. Uses of cash consisted primarily of $50.5 million for dividend payments and $87.1 million for payments on long-term debt.
In fiscal 2017, we entered into an amended credit agreement (“Amended Credit Agreement”), consisting of a $295.1 million term loan and a $750.0 million revolving line of credit. In March 2019, we permanently reduced the capacity under the revolving line of credit to $500.0 million. Interest on borrowings is variable and is determined as a base rate plus a spread. This spread, as well as a commitment fee on the unused portion of the facility, is based on our leverage ratio, as defined in the Amended Credit Agreement. The term loan and revolving credit facilities were initially set to mature no later than January 2022. During the quarter ended October 26, 2019, we repaid the remaining $81.6 million outstanding under the unsecured term loan. As of October 24, 2020, $111.0 million was outstanding under the Amended Credit Agreement revolving line of credit at an interest rate of 1.60%. As of April 25, 2020, no amount was outstanding under the revolving line of credit.
In December 2019, we entered into a senior unsecured term loan facility agreement (the “Term Facility Agreement”), consisting of a $300.0 million term loan. Interest on borrowings is variable and is determined as a base rate plus a spread. This spread is based on our leverage ratio, as defined in the Term Facility Agreement. The proceeds were used to repay certain existing indebtedness, pay fees and expenses incurred in connection with the Term Facility Agreement, and finance our ongoing working capital and other general corporate purposes. The Term Facility will mature no later than December 2022. As of October 24, 2020, $300.0 million was outstanding under the Term Facility at an interest rate of 1.65%. As of April 25, 2020, $300.0 million was outstanding under the Term Facility at an interest rate of 1.87%.
We expect the collection of deferred purchase price receivables, existing cash balances and credit availability under existing debt facilities, less our funds used in operations, will be sufficient to meet our working capital needs and to finance our business over the remainder of fiscal 2021.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
See Note 1 to the Condensed Consolidated Financial Statements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes in our exposure to market risk from that disclosed in Item 7A in our 2020 Annual Report on Form 10-K filed June 24, 2020.
ITEM 4. CONTROLS AND PROCEDURES
Under the supervision and with the participation of our management, including our President and Chief Executive Officer ("CEO") and our Chief Financial Officer ("CFO"), management evaluated the effectiveness of the design and
26

Table of Contents
operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of October 24, 2020. Based upon their evaluation of these disclosure controls and procedures, the CEO and CFO concluded that the disclosure controls and procedures were effective as of October 24, 2020.
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended October 24, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27

Table of Contents
PART II—OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
See Note 10 to the Condensed Consolidated Financial Statements appearing in Part I, Item 1 of this Quarterly Report on Form 10-Q.
ITEM 1A. RISK FACTORS
Except as noted below, there have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors” of Patterson’s Annual Report on Form 10-K for the fiscal year ended April 25, 2020:
The COVID-19 pandemic and measures taken in response thereto have and may continue to have adverse effects on our results of operations and our financial condition, and the full impact of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted.
Global health concerns relating to the COVID-19 pandemic have had, and may continue to have, an impact on the macroeconomic environment, and the pandemic has significantly increased unemployment and economic uncertainty. There continues to be uncertainty around its duration, ultimate impact, and the timing and availability of effective treatments or vaccines. Authorities initially implemented numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter in place orders, and business shutdowns, and have continued to implement such measures as new waves of infection have developed. These measures have, and may continue to have, negative impacts on consumer spending and business spending habits, and they also adversely impacted and may further impact our financial results and the financial results of our customers, suppliers and business partners.
In particular, in March 2020, based upon the recommendations of the American Dental Association, the American Veterinary Medical Association and such organizations’ state-level counterparts, various dental and veterinary offices announced that they were performing only emergency or limited procedures, and rescheduled wellness exams and other elective procedures. In addition, many states and countries imposed restrictions on business operations to protect public health. Although measures have been lifted in some areas that we serve, sometimes subject to social distancing and capacity restrictions, patient volumes remain lower than pre-pandemic levels. Future closures may, and are likely to, be mandated or recommended by health authorities in some states, cities, or counties depending on the progress of the pandemic. In addition, even if dental and veterinary offices are open for business in their area, some consumers may continue to delay elective visits, especially as markets in which we operate experience new waves of infection. In addition, the pandemic has had, and may continue to have, negative impacts on consumer spending and business spending habits due to increased unemployment and economic uncertainty, all of which may become heightened concerns upon new waves of infection or future developments.
Other actual and potential impacts on us from the COVID-19 pandemic include, but are not limited to:
•Interruptions in the operations of industries in which our products are used, including production animal processing. We have experienced, and may continue to experience, significant disruption and economic impact from closures of dental and veterinary offices, as discussed above. In addition, the interruption in meatpacking operations that occurred due to the pandemic factored into the full goodwill impairment of the animal health business in fiscal 2020.
•Limited supply of the personal protective equipment (PPE) necessary for dental practice. Supply chain disruptions for PPE and an increased demand for these products has resulted, and may continue to result, in backorders of PPE and a potential scarcity in raw materials to make PPE. Prices for PPE have also increased, and we have had to prepay suppliers in order to obtain PPE for resale to our customers. We may not be able to supply our customers with the quantity of PPE products they demand. Conversely, PPE demand could decrease suddenly upon an oversupply relative to demand, depending upon the course of the pandemic, which could impact our margins.
•Actual and potential delays in customer payments, defaults on our customer credit arrangements; or other failures by third parties such as suppliers, manufacturers, and distributors to meet their obligations to our company due to their economic circumstances. We have experienced, and may continue to experience, delayed or deferred payments from customers as they, in turn, have been affected by the pandemic. This
28

Table of Contents
impacts our cash flow. There is no assurance when, or if, our customers will be able to resume pre-pandemic payment processes or we will be able to collect all deferred payments.
•Risks of remote work. Most of our corporate employees shifted abruptly to working remotely under stay-at-home orders imposed in March 2020. While such orders are beginning to lift, often subject to social distancing and capacity restrictions, some have been re-imposed and there is no assurance that others will not be re-imposed or recommended in the future depending on the progression of the pandemic, and many of our employees have continued to work remotely. Remote work arrangements could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to efficiently operate our business. In addition, our rapid transition to remote work arrangements for corporate employees could expose us to continuing cybersecurity risk.
•Adapting business practices. The spread of COVID-19 has caused us to modify our business practices, particularly with respect to our liquidity position and near-term cost structure (including through incremental borrowings on our revolving credit facility to increase cash, reduction of non-critical capital expenditures, temporary executive, board, and other senior-level employee compensation reductions, employee furloughs, discretionary spending deferrals and the deferral of payroll taxes under the CARES Act).
•Potential impact on our ability to meet obligations under credit facilities. The pandemic could impact our ability to meet our obligations under our amended credit agreement and other outstanding debt, which may require us to seek covenant relief for a limited period of time. Although there can be no assurance that such relief would be available, if such relief is available, our lenders may, in exchange, increase the cost of borrowing, apply more stringent covenants, restrict merger and acquisition activity, and require other terms and conditions that may limit our business and financing activities.
•Disruptions in the financial markets, which could affect our stock price, our ability to meet covenants under our credit agreement and other outstanding debt, or our ability to secure future debt at acceptable rates.
•Personnel resources. Mitigating the effects of COVID-19 has required, and will likely continue to require for the duration of the pandemic, a large investment of time and resources across our company, and may delay certain strategic and other plans which could materially adversely affect our business. Furthermore, we could be impacted by reduced availability of members of management or employees due to quarantine, illness or death.
•Reputational risk associated with response to COVID-19. If we do not respond appropriately to the COVID-19 pandemic, or if customers do not perceive our response to be adequate, we could suffer damage to our reputation and our brands, which could materially adversely affect our business.
•Interruptions in manufacturing or distribution of our products. Outbreaks in the communities in which we operate could affect our ability to operate our manufacturing or distribution activities, and our suppliers could experience similar interruptions.
The full extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the outbreak within the U.S., Canada and the U.K., its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after COVID-19 has subsided, we may continue to experience materially adverse impacts to our business as a result of its global economic impact, including any recession that has occurred or may occur in the future. There are no comparable recent events which may provide guidance as to the effect of the spread of COVID-19, and, as a result, the ultimate impact of COVID-19, or a similar health epidemic or pandemic, is highly uncertain and subject to change. We do not yet know the full extent of the impacts on our dental and animal health businesses, our operations or the global economy as a whole. However, the effects could have a material impact on our results of operations.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Purchases of Equity Securities by the Issuer
On March 13, 2018, the Board of Directors authorized a $500 million share repurchase program through March 13, 2021. No shares were repurchased under the stock repurchase plan during the second quarter of fiscal 2021.
29

Table of Contents
In fiscal 2017, we entered into an amended credit agreement (“Amended Credit Agreement”), consisting of a $295.1 million term loan and a $750 million revolving line of credit. In March 2019, we permanently reduced the capacity under the revolving line of credit to $500 million. In fiscal 2020, we entered into a senior unsecured term loan facility agreement (the "Term Loan Facility Agreement"), consisting of a $300 million term loan. The Amended Credit Agreement and the Term Loan Facility Agreement permit us to declare and pay dividends, and repurchase shares, provided that no default or unmatured default exists and that we are in compliance with applicable financial covenants.
30

Table of Contents
ITEM 6. EXHIBITS

Exhibit No. |  | Exhibit Description
10.1 |  | Third Amended and Restated Receivables Purchase Agreement, dated as of December 3, 2010, among PDC Funding Company, LLC, as seller, Patterson Companies, Inc., as servicer, the conduits party thereto, the financial institutions party thereto, the purchaser agents party thereto, and MUFG Bank, Ltd. (f.k.a. The Bank of Tokyo-Mitsubishi UFJ, Ltd.), as agent, conformed through Nineteenth Amendment dated, October 19, 2020 (filed herewith).
10.2 |  | Receivables Purchase Agreement, dated as of July 24, 2018, by and among Patterson Dental Supply, Inc., as servicer, PDC Funding Company III, LLC, as seller, purchasers from time to time party thereto, and MUFG Bank, Ltd., as agent, conformed through Sixth Amendment, dated September 30, 2020 (filed herewith).
10.3 |  | Receivables Purchase Agreement, dated as of January 15, 2020, by and among Patterson Veterinary Supply, Inc., as servicer, PDC Funding Company IV, LLC, as seller, purchasers from time to time party thereto, and MUFG Bank, Ltd., as agent, conformed through Third Amendment, dated September 30, 2020 (filed herewith).
31.1 |  | Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 |  | Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 |  | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 |  | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 |  | (Filed Electronically) The following financial information from our Quarterly Report on Form 10-Q for the period ended October 24, 2020, formatted in Inline XBRL (Extensible Business Reporting Language): (i) the condensed consolidated balance sheets, (ii) the condensed consolidated statements of operations and other comprehensive income, (iii) the condensed consolidated statements of changes in stockholders’ equity, (iv) the condensed consolidated statements of cash flows and (v) the notes to the condensed consolidated financial statements.(*)
104 |  | (Filed Electronically) The cover page from our Quarterly Report on Form 10-Q for the period ended October 24, 2020 is formatted in Inline XBRL (Extensible Business Reporting Language).(*)

(*) The Inline XBRL related information in Exhibits 101 and 104 to this Quarterly Report on Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
All other items under Part II have been omitted because they are inapplicable or the answers are negative, or were previously reported in the 2020 Annual Report on Form 10-K filed June 24, 2020.
31

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  | PATTERSON COMPANIES, INC.
|  |  | (Registrant)
Dated: December 2, 2020 | By: |  | /s/ Donald J. Zurbay
|  |  | Donald J. Zurbay
|  |  | Chief Financial Officer and Treasurer
|  |  | (Principal Financial Officer and Principal Accounting Officer)

32